Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
 
 Principal Investigator:   Michael M. Goodman, MD   
     Hem/Onc Staff Physician 
W.G. (Bill) Hefner VA, Salisbury, NC 
Wake Forest School of Medicine  
Medical Center Boulevard Winston- Salem,  NC 27157 
 
Co-Investigator(s):    Christopher Y. Thomas, MD  
Section on Hematology and Oncology  
Wake Forest School of Medicine  
 
Pierre Triozzi, MD  
Section on Hematology and Oncology  
Wake Forest School of Medicine  
 
 Rhonda L. Bitting, MD   
 Section on Hematology and Oncology  
 Wake Forest University Health Sciences  
 
 
Biostatistician:  Janet Tooze, PhD  
Comprehensive Cancer Center of Wake Forest University  
  
Study Coordinator (s):  Jennifer Ward Thomas, MHA, RN, BSN  
Comprehensive Cancer Center of Wake Forest University  
 
 
Data Manager :   Deanna Hissim  
Comprehensive Cancer Center of Wake Forest University  
  
Regulatory Contact:    Alexandra Bolick, MBA  
Compr ehensive Cancer Center of Wake Forest University  
      
Participating Institution:   Comprehensive Cancer Center of Wake Forest University  
     
  
Version Date:   03/10/2020  ClinicalT rials.gov:   [STUDY_ID_REMOVED]  
12/13/2019  
11/18/2019  
05/17/2018  
Amended:    01/19/2018  
04/07/2017  
01/17/2017  
07/12/2016  
    06/23/2016   
    04/06/2016  
    01/26/2016  
Original Version:   10/29/2015  
Confidential
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 2 of 85  
Table of Contents  
SCHEMA  ................................................................................................................................... 5 
1.0 Introduction and Background .......................................................................................... 5 
1.1 Rationale for current study  .......................................................................................... 6 
1.2 Rationale for Dose Selection/Regimen/Modification ................................................... 7 
2.0 Hypothesis and Objectives  ............................................................................................. 9 
2.1 Primary Objective  ....................................................................................................... 9 
2.2 Secondar y Objectives  .................................................................................................  9 
2.3 Correlative Objectives  .................................................................................................  9 
3.0 Patient Selection  ............................................................................................................ 9 
3.1 Inclusion Criteria  ......................................................................................................... 9 
3.2 Exclus ion Criteria  .......................................................................................................11 
3.3 Inclusion of Women and Minorities  ............................................................................12 
4.0 Registration Procedures  ................................................................................................13 
5.0 Study Outcomes and Study Measures ...........................................................................13 
5.1 Primary Outcome  .......................................................................................................13 
5.2 Secondary Outcomes  ................................................................................................13 
5.3 Correlative Outcomes  ................................................................................................13 
6.0 Treatment Plan ..............................................................................................................14 
6.1 Study schema  ............................................................................................................14 
6.2 Study -Related Activities  .............................................................................................14 
6.2.1  Informed Consent  ................................................................................................17 
6.2.2  Inclusion/Exclusion Criteria ..................................................................................17 
6.2.3  Medical History  ....................................................................................................17  
6.2.4  Prior and Concom itant Medications Review  .........................................................18 
6.2.5  Disease Details and Treatments  ..........................................................................18 
6.2.6  Adverse Event (AE) Monitoring ............................................................................18 
6.2.7  Physical Exam  .....................................................................................................19 
6.2.8  Laboratory Procedures/Assessments  ..................................................................19 
6.3 Treatment Administration ...........................................................................................19 
6.4 General Concomitant Medication and Supportive Care Guidelines  ............................21 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 3 of 85 6.4.1  Acceptable Concomitant Medications  ..................................................................21 
6.4.2  Prohibited Concomitant Medications  ....................................................................21 
6.4.3  Supportive Care Guidelines  .................................................................................22 
6.5 Other Considerations  ................................................................................................. 33 
6.5.1  Contraception ......................................................................................................33 
6.5.2  Use in Pregnancy  ................................................................................................34 
6.5.3  Use in Nursing Women  ........................................................................................34 
6.6 Duration of Therapy  ...................................................................................................34 
6.7 Post-treatment Visits ..................................................................................................35 
6.7.1  Safety Follow -up Visit (End -of-treatment visit) ......................................................35 
6.7.2  Follow Up .................................................................................................................36 
7.0 Dosing Delays/Dose Modifications  ................................................................................36 
7.1  Pembrolizumab ...............................................................................................................36 
7.2   Paclitaxel ...........................................................................................................................39 
8.0 Measurement of Effect  ..................................................................................................40 
8.1 Antitumor Effect  .........................................................................................................40 
8.1.1  Definitions  ............................................................................................................40 
8.1.2  Methods for Evaluation of Measurable Disease ...................................................42 
8.1.3  Response Criteria ................................................................................................42 
8.1.4  Evaluation of Non -Target Lesions  ........................................................................42 
8.1.5  Evaluation of Best Overall Response ................................................................... 43 
8.1.6  Duration of Response  ..........................................................................................44 
8.1.7  Survival Outcomes  ...............................................................................................45 
8.1.8  Response Review  ................................................................................................45 
9.0 Adverse Events List and Reporting Requirements  .........................................................45 
9.1 Assessing and Recording Adverse Events  ................................................................45 
9.1.1  Serious Adverse Events  .......................................................................................46 
9.1.2  Events of Clinical Interest .....................................................................................47  
9.1.3  Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor and to Merck  ........................................................................................................48 
9.1.4  Merck Requirements for Evaluating Adverse Events  ............................................49 
9.2 Adverse Event Characteristics  ...................................................................................50 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 4 of 85 9.3 STRC SAE Reporting Requirements  .........................................................................51 
9.4  WFUHS IRB AE Reporting Requirements  ................................................................. 51 
9.5 Merck Reporting Requirements  .................................................................................52 
9.5.1  Reporting of Pregnancy and Lactation to the Sponsor and to Merck  ....................52 
9.5.2  Reporting of SAEs and Events of Clinical Interest  ................................................52 
10.0  Pharmaceutical Information ...........................................................................................53 
10.1  Pharmaceutical Accountability  ...................................................................................53 
10.2  Pembrolizumab ..........................................................................................................53 
10.3  Paclitaxel  ...................................................................................................................55 
11.0  Correlative/Special Studies  ............................................................................................ 56 
11.1  Laboratory Correlative Studies  ..................................................................................56 
12.0  Data Management  .........................................................................................................58 
13.0  Statistical Considerations  .............................................................................................. 58 
13.1  Power, Sample Size and Accrual Rate  ......................................................................58 
13.2  Analysis of Primary Objective  ....................................................................................58 
13.3  Analysis of Secondary Objectives  ..............................................................................58 
13.4  Analysis of Correlative Objectives ..............................................................................59 
References  ...............................................................................................................................59 
Appendix A – Protocol Registration Form  ..................................................................................62 
Appendix B – Subject Eligibility Checklist  ..................................................................................63 
Appendix C –  Race & Ethnicity Verification Form  ......................................................................67 
Appendix D –  Mandatory STRC SAE Reporting Guidelines  ......................................................68 
Appendix E – TUMOR RESPONSE WORKSHEET (RECIST v1.1)  ..........................................75 
Appendix F –  Baseline Data Collection Form  ............................................................................79 
Appendix G –  Follow -up Data Collection Forms  ........................................................................82 
Appendix H –  Treatment Response Evaluation .........................................................................84 
Appendix I –  Adverse Event Log ...............................................................................................85 
 
 
 
 
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 5 of 85 SCHEMA  
 
 
This will be a single -arm, open label, phase 2 study with the following schema:  
 
 
 
 
1.0 Introduction and Background  
 
In the United States, approximately 74,000 new cases of urothelial cancer (UC) and 
16,000 deaths from UC are expected in 2015.  Patients with distant metastases at the time 
of diagnosis have only a 6% likelihood of being alive in 5 years; therefore, improvement in 
the treatment of advanced UC is urgently needed.1  The standard -of-care for first -line 
systemic treatment for patients with metastatic UC is platinum -based combination 
chemotherapy .2  Response rates are about 50%, with durable responses seen in a small 
fraction of patients.  However, many patients are not eligible for cisplatin- based regimens 
due to renal insufficiency or suboptimal clinical status.  For patients who are eligible and are treated, nearly all are destined to progress.  Second- line therapy using a variety of 
cytotoxic agents can be given, but response rates are low and there is no accepted standard.     
  
Therapi es that target the programmed death- 1 (PD -1) and the PD -1 ligand (PD -L1) 
interaction are promising treatments for a variety of solid tumors.  The PD -1 receptor is 
normally expressed on activated T- cells, and when it encounters its ligand, PD -L1, the T-
cell is inactivated.  Both tumor cells and tumor -associated lymphocytes may express PD-
L1 and therefore evade host immune surveillance.  Disruption of the PD -1/PD -L1 
interaction maintains and enhances effector T cell responses, thereby leading to tumor 
regress ion.3,4  This is now possible due to the development of agents that interact with 
one of the two molecules.  Among these is pembrolizumab, a monoclonal antibody that  
binds the PD -1 receptor .   
 

Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 6 of 85 Pembrolizumab treatment can induce tumor regression, including in patients with 
metastatic urothelial cancer.  In KEYNOTE -012, a phase 1b study of pembrolizumab in 
patients with PD -L1-positive solid tumors, almost 10% of patients with advanced UC had 
a complete response to therapy and nearly a quarter of patients had no evidence of 
disease progression at 6 months.  The overall response rate in the study for patients with 
UC was seven of 29 (24%); therefore, while pembrolizumab shows promise as a 
monotherapy, there is need for improvement .5 
 
In general, immunotherapeutic approaches for advanced UC have had limited success 
due to profound inflammation- associat ed immune suppression.  M yeloid derived 
suppressor cells (MDSC) with potent T- cell suppressive activities are increased in UC .6,7  
UC is also dominated by T- regulatory (Treg) cells and immune inhibitory cytokines .8 
Antitumor T- cell responses in UC are i nhibited by MDSC and Treg cells, which increase 
with cytotoxic chemotherapy .9  PD-1 blockade only partially overcomes this MDSC and 
Treg cell suppression in tumor models ,10 and the effect of treatment with immune 
checkpoint inhibitors is maximized when MDSCs are fully eradicated.11  Preclinical studies  
in UC models similarly highlight the need to abrogate immune suppression to maximize 
the antitumor efficacy of PD -1 blockade .12  Therefore, t he efficacy of pembrolizumab may 
be enhanced when given in combination with agents that augment antitumor immune 
responses.    
 
Single -agent taxanes are commonly used to treat patients with platinum -refractory UC, 
however response rates are modest at 5- 15%, with no known survival benefit .13-15  
Although the antitumor effects of taxanes are g enerally attributed to effects on 
microtubules and cell division, there is increasing evidence that taxanes are also 
immunomodulatory.  Several studies have shown that treatment with low -dose taxanes 
reduces MDSC and Treg cells and modifies the tumor microenvironment to promote 
immunogenic tumor death.16,17  Paclitaxel can inhibit MDSC and restore CD8 T -cell 
effector function, and low -dose cytotoxic therapy enhances the antitumor activity of anti -
PD-1 antibody in mouse model systems .18-20  Overall, the role of chemotherapy to target 
immunosuppressive cells and improve treatment of advanced cancer is increasingly 
recognized.21  The use of taxanes  at non -cytotoxic doses to block the 
immunosuppressive potential of MDS C and Treg cells is a new therapeutic strategy 
for enhancing the efficacy of anti -PD-1 immunotherapy with pembrolizumab.    
 
1.1 Rationale for current study  
 
The effects of pembrolizumab with chemotherapy on immune regulatory 
mechanisms in cancer patients, in general, and in patients with the highly 
inflammatory UC, specifically, are not known.  Fur thermore, biomarkers predictive 
of pembrolizumab response are needed.  Assess ment of  tumor  expression of PD -
1 ligands, which can be technically challenging, has not been consistently 
informative .22,23  Of note,  PD-L1 is widely expressed by UC tumor cells but is not 
prognostic; PD -L1 expression in UC tumor infiltrating mononuclear cells, in 
contrast, is associated with longer survival .24  Antigen -specific T cells, T cell 
effector and suppressor cells, and MDSC populations have also been asses sed to 
predict PD -1 blockade response, but results have been inconclusive.25,26  
microRNAs (miRs), small non -coding RNAs that regulate multiple processes at the 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 7 of 85 post-transcriptional level, are emerging as important biomarkers.  miRs are easily 
measureable by polymerase chain reaction (PCR) techniques in most biofluids, 
and the diagnostic and prognostic utility of measuring blood and urine miRs in 
patients with UC are under investigation .27-29  Epigenetic mechanisms of immune 
response are increasingly being recognized, and sev eral miRs with immune 
regulatory activities have been identified.  For example, in melanoma and in 
prostate cancer, chang es in specific plasma miRs are associated with changes in 
circulating natural killer, dendritic, and T, MDSC, and Treg cells .30,31 
 
To evaluate the potential synergy of paclitaxel and pembrolizumab, we propose a 
single -arm combination study of pembrolizumab and paclitaxel in patients with 
platinum -refractory metastatic UC.   We hypothesize that combination therapy will 
double the overal l response rate as compared to single- agent pembrolizumab 
alone.  We also incorporate multiple novel biomarker studies.  This trial may lead 
to improved therapy for advanced UC and may also suggest specific interventions 
to improve antitumor immunologic ac tivity.  
1.2 Rationale for Dose Selection/Regimen/Modification  
 
The first in human study of pembrolizumab (MK-3475) showed evidence of target 
engagement and objective evidence of tumor size reduction at all dose levels (1 
mg/kg, 3 mg/kg and 10 mg/kg Q2W).  Recent data from other clinical studies within 
the MK -3475 program has shown that a lower dose of MK -3475 and a less frequent 
schedule may be sufficient for target engagement and clinical activity.  
 
PK data analysis of MK -3475 administered Q2W and Q3W show ed slow systemic 
clearance, limited volume of distribution, and a long half -life.  Pharmacodynamic 
data (IL -2 release assay) suggested that peripheral target engagement is durable 
(>21 days).  This early PK and pharmacodynamic data provides scientific rati onale 
for testing a Q2W and Q3W dosing schedule.   
 
A population pharmacokinetic analysis was performed using serum concentration 
time data from 476 patients.  Within the resulting population PK model, clearance 
and volume parameters of MK -3475 were found to be dependent on body weight. 
The relationship between clearance and body weight, with an allometric exponent 
of 0.59, is within the range observed for other antibodies and would support both 
body weight normalized dosing or a fixed dose across all body weights.  MK -3475 
has been found to have a wide therapeutic range based on the melanoma indication.  The differences in exposure for a 200 mg fixed dose regimen relative 
to a 2 mg/kg Q3W body weight based regimen are anticipated to remain well within 
the e stablished exposure margins of 0.5 –  5.0 for MK -3475 in the melanoma 
indication. The exposure margins are based on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the proposed dose regimen of 2 mg/kg 
Q3W (i.e. 5 -fold higher dose and exposure). The population PK evaluation 
revealed that there was no significant impact of tumor burden on exposure. In 
addition, exposure was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in exposure betw een different 
indication settings.  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 8 of 85 The rationale for further exploration of 2 mg/kg and comparable doses of 
pembrolizumab in solid tumors is based on: 1) similar efficacy and safety of 
pembrolizumab when dosed at either 2 mg/kg or 10 mg/kg Q3W in melanoma  
patients, 2) the flat exposure- response relationships of pembrolizumab for both 
efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the 
lack of effect of tumor burden or indication on distribution behavior of 
pembrolizumab (as assess ed by the population PK model) and 4) the assumption 
that the dynamics of pembrolizumab target engagement will not vary meaningfully 
with tumor type.  
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed 
dosing is based on simulations  performed using the population PK model of 
pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide 
exposures that 1) are optimally consistent with those obtained with the 2 mg/kg 
dose every 3 weeks, 2) will maintain individual patient exposures in the exposure 
range established in melanoma as associated with maximal efficacy response and 
3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.  
The rationale for com bination therapy is supported by Merck’s preclinical work, in 
which a murine immunocompetent cancer model was treated with the anti -mouse 
PD-1 antibody in combination with 4 different chemotherapy regimens, including 
dexamethasone premedication at dose lev els 0.5, 1, or 5 mg/kg.   The results 
revealed that none of the combinations had a negative impact on the efficacy of 
anti–PD-1 treatment.  Several treatment regimens, including those in combination 
with paclitaxel, resulted in a greater antitumor effect, including some complete 
responses, than treatment with either chemotherapy or PD -1 inhibition alone.    
 There are multiple ongoing clinical studies of pembrolizumab in combination with 
chemotherapy.  For example, Merck 021 is U.S. -based a phase I/II study of 
pembrolizumab in combination with multiple chemotherapy regimens, including paclitaxel, for patients with NSCLC.   The chemotherapy in this and other studies 
is given in cytotoxic doses, and thus far there have been no significant safety 
issues reported.    
Paclitaxel is commonly used to treat patients with platinum -refractory UC.  Multiple 
dosing regimens have been studied.  One small study gave paclitaxel  175 to 250 
mg/m2 by 24- hour infusion every 3 weeks32 and another gave  paclitaxel 200 
mg/m2 by 3-hour infusion33 to pretreated patients with advanced urothelial canc er.  
Both reported some efficacy with manageable toxicity.  Weekly administration of 
paclitaxel at doses rang ing from 80 -100 mg/m2 in patients with breast cancer and 
other solid tumors has shown better tolerance and minimal  immunosuppression.34  
As such, w eekly paclitaxel  at 80 mg/m2 given over 1 hour  was studied in ad vanced  
urothelial carcinoma.  30 patients were treated , and a partial response was seen 
in 10% of patients.  Time to progression was 2.2 months and overall survival 7.2 months.   Treatment was well -tolerated, with anemia, neuropathy, and asthenia the 
most c ommon toxicities reported.
14 Weekly paclitaxel (135mg/m2) and carboplatin 
(AUC 2) has also been studied i n advanced UC, but significant treatment -related 
toxicity was noted. 35 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 9 of 85 Here we are giving  pembrolizumab in combination with weekly paclitaxel at 80 
mg/m2, 2 out of every 3 weeks .   This dosing regimen of paclitaxel  was chosen  
based on clinical studies showing this dose to be safe and preclinical studies 
suggesting that taxanes are immunomodulatory , as described above.  Paclitaxel 
will be given 2 out of every 3 weeks in order to limit myelosuppression and steroid exposure.   The use of paclitaxel at non- cytotoxic doses, to b lock the 
immunosuppressive potential of MDSC and Treg cells , is a new therapeutic 
strategy for enhancing the efficacy of anti -PD-1 immunotherapy with 
pembrolizumab.    
2.0 Hypothesis and Objectives  
 
This study hypothesizes that: 1) Combination therapy with low -dose paclitaxel and 
pembrolizumab will improve the ORR and PFS compared to single- agent pembrolizumab; 
2) Combination of low -dose paclitaxel with pembrolizumab will be safe and adequately 
tolerated ; 3) Combination therapy will result  in: a) Increased number and proportion of 
circulating functional CD8+ T -cells, and b) D ecreased number and proportion of circulating 
MDSC and Treg cells ; and 4) Response will be associated with increased CD8+ T -cells 
and/or decreased MDSC and Treg cells . 
2.1 Primary Objective  
 
2.1.1  To estimate the overall response rate (ORR) of pembrolizumab combined 
with paclitaxel  
2.2 Secondary Objective s 
 
2.2.1  To determine the safety and tolerability of pembrolizumab combined with 
paclitaxel  
2.2.2  To calculate the progression- free survival (PFS) rate at 6 months  
 2.3 Correlative Objectives  
 
2.3.1  To determine the immune effects of pembrolizumab combined with 
paclitaxel  
2.3.2  To associate immune effects with tumor response  
2.3.3  To explore changes in immune -regulatory microRNAs as biomarkers of 
response  
3.0 Patient Selection  
 
3.1 Inclusion Criteria  
 
3.1.1  Patients diagnosed with platinum -refractory metastatic ur othelial cancer 
that is measureable based on Response Evaluation Criteria in Solid 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 10 of 85 Tumors (RECIST) criteria 1.1.36  Platinum -refractory disease is defined as 
progressive disease on cisplatin or carboplatin therapy or within 12 months 
of prior platinum treatment  (last dose. )   
 
3.1.2  At least 1 prior chemotherapy regimen containing cisplatin or carboplatin.   
 
3.1.3  Patient must be  willing to provide tissue from a newly obtained core or 
excisional biopsy of a tumor lesion.  Newly -obtained is defined as a 
specimen obtained up to 6 months  (168 days) prior to initiation of treatment 
on Day 1.  Archived specimen can be used for s ubjects , if available . 
 
3.1.4 Age >18 years.  
 
3.1.5 Performance status of 0 or 1 on the ECOG Performance Scale.  
 
3.1.6 Adequate organ function  as defined below:  
     
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 /mcL  
Platelets  ≥80,000 / mcL  
Hemoglobin  ≥9 g/dL without transfusion dependency  
Renal   
Serum creatinine OR 
Measured or calculated creatinine 
clearance  
(GFR can also be used in place of 
creatinine or CrCl)  ≤1.5 X upper limit of normal (ULN) OR 
 ≥35 mL/min for subject with creatinine levels > 1.5 X 
institutional ULN  
Hepatic   
Serum total bilirubin  ≤ 1.5 X ULN OR 
 Direct bilirubin ≤ ULN for subjects with total bilirubin levels 
> 1.5 X ULN 
AST (SGOT) and ALT (SGPT)  ≤ 2.5 X ULN  OR 
≤ 5 X ULN for subjects with liver metastases  
Albumin  >2.5 mg/dL  
 
3.1.7 Female subject of childbearing potential should have a negative urine or 
serum pregnancy within 72 hours prior to receiving the first dose of study 
medication.  If the urine test is positive or cannot be confirmed as negative, 
a serum pregnancy test will be required.   
3.1.8 Female subjects of childbearing potential should be willing to use 2 
methods of birth control or be surgically sterile, or abstain from 
heterosexual activity for the course of the study through 120 days after the  
last dose of study medi cation. Subjects of childbearing potential are those 
who have not been surgically sterilized or have not been free from menses 
for > 1 year.  
3.1.9 Male subjects should agree to use an adequate method of contraception 
starting with the first dose of study therapy through 120 days after the last 
dose of study therapy.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 11 of 85 3.1.10 Ability to understand and t he willingness to sign an IRB -approved informed 
consent document . 
3.2 Exclusion Criteria   
 
3.2.1  Currently receiving or has  had treatment with an investigational agent or used 
an investigational device within 4 weeks of study Day 1.   
 
3.2.2  Anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or 
who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administ ered more than 4 weeks earlier.  
 3.2.3   Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 
weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at 
baseline) from adverse events due to a previously administered a gent.  
      
 Note:  Subjects with ≤ Grade 2 neuropathy are an exception to this criterion 
and may qualify for the study.  
 
  Note:  If subject received major surgery, they must have recovered adequately 
from the toxicity and/or complications from the intervention prior to starting 
therapy.  
 
3.2.4  Prior therapy with an anti -PD-1, anti -PD-L1, or anti -PD-L2 agent . Prior therapy 
with paclitaxel or docetaxel.  
 
3.2.5  Hyper sensitivity to pembrolizumab, any of its excipients , paclitaxel, or any of 
its excipien ts. 
 
3.2.6  Diagnosis of immunodeficiency  or is receiving systemic steroid therapy or any 
other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.   
 
3.2.7  Known history of active TB   (Bacillus Tuberculosis) . 
 3.2.8  Known additional malignancy that is progressing or requires active treatment.  
Exceptions include basal cell carcinoma of the skin or squamous cell 
carcinoma of the skin that has undergone potentially curative therapy or in situ 
cervical cancer.  
 
3.2.9  Known active central nervous system (CNS) metastases and/or 
carcinomatous meningitis.  Subjects with previously treated brain metastases 
may participate provided they are stable (without evidence of progression by 
imaging for at least four weeks prior to the first dose of trial treatment and any 
neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior 
to trial treatment.   This exception does not include carcinomatous meningitis 
which is excluded regardless of clinical stability.    
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 12 of 85 3.2.10  Active autoimmune disease that has required systemic treatment in the past 2 
years (i.e. with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replac ement therapy (eg., thyroxine, insulin, or 
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.  
 
3.2.11  Known history of, or any evidence of act ive, non -infectious pneumonitis.  
 
3.2.12  Active infection requiring systemic therapy.  
 3.2.13  History or current evidence of any condition, therapy, or laboratory abnormality 
that might confound the results of the trial, interfere with the subject’s participation for the full  duration of the trial, or is not in the best interest of the 
subject to participate, in the opinion of the treating investigator.   
 3.2.14  Known psychiatric or substance abuse disorders that would interfere with 
cooperation with the requirements of the t rial. 
 3.2.15  Pregnancy  or breastfeeding, or expecting to conceive or father children within 
the projected duration of the trial, starting with the pre -screening or screening 
visit through 120 days after the last dose of trial treatment.  
 3.2.16  Known hist ory of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).  
 
3.2.17  Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA 
[qualitative] is detected).  
 
3.2.18  Received a live vaccine within 30 days of planned start of study therapy.  
Note:  Seasonal influenza vaccines for injection are generally inactivated flu 
vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-
Mist®) are live attenuated vaccines,  and are not allowed.  
3.3 Inclusion of Women and Minorities  
 
Men and women of all races and ethnicities who meet the above- described 
eligibility criteria are eligible to participate in this study.  
 
The study consent form will also be provided in Spanish for Spanish- speaking 
participants.  We do not expect the percentage of Hispanic/Latino or racial minority 
cancer patients eligible for this study to be higher than the percentage of Hispanic or racial minority new cancer patients seen at CCCWFU (1.7% and 14.4%,  
respectively); therefore, we plan to enroll at least 1 Hispanic/Latino and at least 4 
racial minority  patient s. 
 Should we not meet or exceed these estimates, the PI will engage the Cancer 
Center Health Equity Advisory Group to discuss strategies to enhance recruitment 
in these target populations.  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 13 of 85 4.0 Registration Procedures  
 
All patients entered on any CCCWFU trial, whether treatment, companion, or cancer control trial, 
must be registered with the CCCWFU Protocol Registrar or entered into ORIS Screening Log 
within 24 hours of Informed Consent. Patients must  be registered prior to the initiation of 
treatment.   
 
You must perform the following steps i n order to ensure prompt registration of your patient : 
 
1. Complete the Eligibility Checklist ( Appendix B ) 
2. Complete the Protocol Registration Form ( Appendix A ) 
3. Alert the Cancer Center registrar by phone, and then send the signed Informed 
Consent Form, Eligibility Checklist and Protocol Registration Form to the registrar, 
either by fax or e -mail.  
 
 
Contact Information:  
Protocol Registrar PHONE (336) 713- 6767  
Protocol Registrar FAX (336) 713 -6772  
Protocol Registrar E -MAIL ( registra@wakehealth.edu ) 
            
*Protocol Registration is open from 8:30 AM -  4:00 PM,  Monday -Friday.  
 
4. Fax/e-mail ALL eligibility source documents with registration. Patients will not  be 
registered without all required supporting documents.  
Note: If labs were performed at an outside institution, provide a printout of the results. 
Ensure that the most recent lab values are sent.  
 To complete the registration process, the Registrar will:   
 
• assign a patient study number  
• register the patient on the study  
5.0 Study Outcomes and Study Measures  
5.1 Primary Outcome  
 
5.1.1  The primary outcome measure will be overall response rate.  
5.2 Secondary Outcomes  
 
5.2.1  Safety, as assessed by adverse events and serious adverse events  
5.2.2  Progression -free survival at 6 months  
 5.3 Correlative Outcomes  
  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 14 of 85 5.3.1  Immune effects, as assessed by changes in the number and proportion of 
functional CD8+ T- cells, MDSCs, Tregs, and circulating immune -regulatory 
microRNAs in peripheral blood 
 
5.3.2  Quantify cytotoxic T- cells, MDSCs, and Tregs and determine the 
correlation of PD -L1 expression in tumor  tissue 
 5.3.3  Changes in serum and urine immune- regulatory microRNAs  
6.0 Treatment Plan  
 
6.1 Study schema  
 
 
 
6.2 Study-Related Activities  
 
The Trial Flow Chart below summarizes the trial procedures to be performed at each visit.  It may be necessary to perform these procedures at unscheduled time points if deemed 
clinically necessary by the investigator.   Furthermore, additional evaluations/testing may 
be deemed necessary by the Sponsor and/or Merck for reasons related to subject safety.  
  
 
 
TRIAL FLOW CHART 
 
 
Procedure  Screeninga  
TREATMENT PHASE  
(UP TO 6 MONTHS)  
 
21 day cycle  
(+/- 3 days)   
MAINTENANCE PHASE  
(UP TO 18 MONTHS)  
 
 

Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 15 of 85 Within 14  days of 
dosing  Day 
1 Day 
8 End of 
Treatment  
Visitb Treatment  
 21 day cyclec  
(+/- 10 days)  Follow -up 
onlyd  
(+/- 10 days)  
Informed consent  X      
Eligibility criteria  X      
Demographic data  X      
Concomitant 
medicationse X X  X   
Medical history  and 
physical exam  X X  X X X 
AE assessmentf X X  X   
Vital signs, height, and 
weightg X X  X   
ECOG performance 
status  X X  X   
Pembrolizumab dosing   X   X  
Paclitaxel dosing   X X    
CT chest, abdomen, 
pelvish X X  X X X 
 
Standard -of-care laboratory assessmentsi 
 
CBC with differential  X X X X X X 
Serum chemistries  X X X X X X 
LDH  X  X   
Complete urinalysis   X  X   
Thyroid studies   X  X X  
Urine pregnancy testj X      
 
Correlative/research studies  
 
Metastatic tumor site 
biopsyk X      
Archival tumor tissuel X      
Blood correlatesm  X  X   
Urinary correlatesm  X  X   
MicroRNA  blood & 
urine correlatesn  X  X   
 
Footnotes to Study Flow Chart : 
a. Screening evaluations must be completed within 14 days of first dose of medication and DO NOT need 
to be repeated on cycle 1 day 1 of treatment , except for the labs (CBC/CMP) which need to be 
performed within 72 hours of first dose.   CT scan of chest/abdomen/pelvis can be within 30 days of 
cycle 1 day 1.  Contrast scans preferred but noncontrasted studies acceptable if renal insufficiency, 
contrast allergy, or other medical condition prohibits the use of contrast.  
 
b. The End of T reatment Visit is to occur no more than 30 days after the last dose of study agent.  At the 
End of Treatment V isit, if progressive disease, patient will be followed for survival status .  If stable 
disease or partial or complete response, patient will  have the option of remaining on pembrolizumab 
alone for an additional 18 months or until disease progression.    
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 16 of 85 c. Patients who remain on pembrolizumab in the maintenance phase will be seen every 21 days, with 
imaging every 3 months (+/ - 10 days) for up to 18 months.  
 
d. Patients  who do not have progressive disease but who decline maintenance pembrolizumab will be 
followed every 3 months (+/ - 10 days) for up to 18 months after the End of Treatment  Visit.  These 
patients will have scans every 3 months  (+/- 10 days) .  All patients will continue to be followed for 
survival status .   
 
e. All concomitant medications received within 28 days before the first dose of trial treatment and 30 days 
after the treatment phase  should be recorded, including all prescription, over -the-counter (OTC), herbal 
supplements, and IV medications and fluids . 
 f. Medical history, physical examination and AE assessments will be performed prior to study agent 
administration, on day 1 of each cycle.  An end- of-study medical history, phys ical exam, and AE 
assessment will be performed at the end of treatment  phase.    
 
g. Vital signs and weight will be recorded at each visit  during the treatment phase.  Height will be measured 
at screening only.     
h. Contrast scans preferred but noncontrasted st udies acceptable if renal insufficiency, contrast allergy, 
or other medical condition prohibits the use of contrast.  CT scan of chest/abdomen/pelvis can be within 
30 days of cycle 1 day 1.   
TREATMENT PHASE:  CT scan of chest/abdomen/pelvis t o be performed on day 1 of cycle  
4, day 1 of cycle 7, and at the end- of-treatment visit  (+/-7 days)  as part of routine tumor 
assessment.   
MAINTENANCE PHASE:  CT scan of chest/abdomen/pelvis  to be performed every 3 months (+/ -  
10 days) as part of routine tumor assessment.   
 
These tumor assessments will be performed locally, in accordance with the RECIST 1.1 guidelines .   
 
i. Standard- of-care laboratory assessments at the times indicated include:   
Complete blood count (CBC) with differential : WBC count with differential, platelet count, hemoglobin, 
and hematocrit.  
Serum chemistries:   Sodium, potassium, chloride, blood urea nitrogen (BUN), creatinine, glucose, 
carbon dioxide or bicarbonate, calcium, protein, albumin, aspartate aminotransferase (AST), alan ine 
aminotransferase (ALT), total bilirubin, a nd alkaline phosphatase.  Note: During maintenance phase, 
order BMP except on visits where thyroid testing is included (order CMP .) 
LDH 
Urinalysis :  Including pH, specific gravity, protein, microscopy, hemoglobin, cell count, crystal 
evaluation, leukocyte esterase, and nitrite without culture will be collected on day 1 of cycles 1, 4, 8, 
and at the end of treatment  visit. 
Thyroid studies :  TSH, free T4, and T3 will be performed on day 1 of cycles 1, 4, 8, and at the end of 
treatment  visit due to the potential for thyroid abnormalities while on pembrolizumab.  Note:  In the 
maintenance phase, thyroid studies will be performed every 3 cycles.  
Note : Day 1 lab tests do not have to be repeated if screening labs  are obtained within 3 days  prior to 
the first dose of study drug.   
 
j. Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as 
negative, a serum pregnancy test will be required.   
 
k. If safely able to be performed, a  metastatic (bone, soft tissue, visceral metastasis permitted) or recurrent 
bladder tumor biopsy under radiologic or cystoscopic guidance will be performed prior to treatment 
initiation.  Biopsies obtained up to 6 months (168 days ) prior to treatment initi ation are acceptable.  
    
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 17 of 85 l. Previously archived formalin- fixed or frozen tumor blocks will be collected on this study and linked to 
subject outcomes if available.  Frozen primary tumor samples will be collected if available.  
 
m. Blood and urine correlates will  be collected prior to treatment administration on day 1 of cycle 1, day 1 
of cycle 4, day 1 of cycle 8 , and at the end of treatment  visit.   
 
n. Blood and urine for microRNA analysis will be collected prior to treatment administration on day 1 of 
cycle 1, da y 1 of cycle 4,  day 1 of cycle 8, and at the end of treatment  visit.   
 
6.2.1 Informed Consent  
The Investigator must obtain documented consent from each potential subject prior 
to participating in a clinical trial.  
 
Consent must be documented by the subject’s dated signature or by the subject’s 
legally acceptable representative’s dated signature on a consent form along with 
the dated signature of the person conducting the consent discussion.  
 
A copy of the signed and  dated consent form should be given to the subject before 
participation in the trial.  
 
The initial informed consent form, any subsequent revised written informed 
consent form and any written information provided to the subject must receive the 
IRB/ERC’s ap proval/favorable opinion in advance of use.  The subject or his/her 
legally acceptable representative should be informed in a timely manner if new 
information becomes available that may be relevant to the subject’s willingness to 
continue participation in the trial.  The communication of this information will be 
provided and documented via a revised consent form or addendum to the original 
consent form that captures the subject’s dated signature or by the subject’s legally 
acceptable representative’s dated signature.  
 
Specifics about a trial and the trial population will be added to the consent form 
template at the protocol level.   
 
The informed consent will adhere to IRB/ERC requirements, applicable laws and 
regulations and Sponsor requirements.  
6.2.2 Inclusion/Exclusion Criteria  
 
All inclusion and exclusion criteria will be reviewed by the investigator or qualified 
designee to ensure that the subject qualifies for the trial.  
6.2.3 Medical History  
A medical history will be obtained by the investigator or q ualified designee.  
Medical history will include all active conditions, and any condition diagnosed 
within the prior 10 years that are considered to be clinically significant by the 
Investigator.  Details regarding the disease for which the subject has enr olled in 
this study will be recorded separately and not listed as medical history.   
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 18 of 85 6.2.4 Prior and Concomitant Medications Review  
 
Prior Medications  
The investigator or qualified designee will review prior medication use, including 
any protocol -specified washout requirement, and record prior medication taken by 
the subject within 28 days before starting the trial.  Treatment for the disease for 
which the subject has enrolled in this study will be recorded separately and not 
listed as a prior medication.  
 
Concomitant Medications 
The investigator or qualified designee will record medication, if any, taken by the 
subject during the trial.  All medications related to reportable SAEs and ECIs 
should be recorded as defined in Section 9.0 . 
6.2.5 Disease Details and Treatments  
Disease Details  
The investigator or qualified designee will obtain prior and current details regarding 
disease status.  
 Prior Treatment Details  
The investigator or qualified designee will review all prior cancer treatments 
including systemi c treatments, radiation and surgeries.  
 
Subsequent Anti -Cancer Therapy Status  
The investigator or qualified designee will review all new anti -neoplastic therapy 
initiated after the last dose of trial treatment.  If a subject initiates a new anti -cancer 
therapy within 30 days after the last dose of trial treatment, the 30 day Safety 
Follow -up visit must occur before the first dose of the new therapy.  Once new anti -
cancer therapy has been initiated the subject will move into survival follow -up.  
6.2.6 Advers e Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for 
potential new or worsening AEs as specified in the Trial Flow Chart and more 
frequently if clinically indicated.  Adverse experiences will be graded and recorded 
throughout the treatment phase of the study according to NCI CTCAE Version 4.0 
(see Section 9.0 ).  Toxicities will be characterized in terms regarding seriousness, 
causality, toxicity grading, and action taken with regard to trial treatment.  
  
For subjects receiving treatment with pembrolizumab all AEs of unknown etiology 
associated with pembrolizumab exposure should be evaluated to determine if it is 
possibly an event of clinical interest (ECI) of a potentially immunologic etiology 
(termed immu ne-related adverse events, or irAEs); see the separate ECI guidance 
document regarding the identification, evaluation and management of potential irAEs.   
 
Please refer to section 9.0 for detailed information regarding the assessment and 
recording of AEs.   
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 19 of 85 6.2.7 Physical Exam  
The investigator or qualified designee will perform a complete physical exam 
during the screening period.  Clinically significant abnormal findings should be 
recorded as medical history.   
 
For cycles that do not require a full physic al exam per the Trial Flow Chart, the 
investigator or qualified designee will perform a directed physical exam as clinically 
indicated prior to trial treatment administration.   
 
Vital Signs  
The investigator or qualified designee will take vital signs at s creening, prior to the 
administration of each dose of trial treatment and at treatment discontinuation as 
specified in the Trial Flow Chart (Section 6.0).  Vital signs should include 
temperature, pulse, respiratory rate, weight and blood pressure.  Height will be 
measured at screening only.  
 Eastern Cooperative Oncology Group (ECOG) Performance Scale  
The investigator or qualified designee will assess ECOG status (see Section 11.1) at screening, prior to the administration of each dose of trial treatment and  
discontinuation of trial treatment as specified in the Trial Flow Chart.   
6.2.8 Laboratory Procedures/Assessments  
Laboratory tests for screening  should be performed within 14 days prior  to the first 
dose of treatment and will need to be repeated if not within 72 hours of first dose.   
After cycle 1 day 1, all pre- dose laboratory procedures can be conducted up to 72 
hours prior to dosing.  Results must be reviewed by the investigator or qualified 
designee and found to be acceptable prior to each dose of trial treatment.  
 
Blood and urine correlates will be collected prior to treatment administration on day 
1 of cycle s 1, 4, 8, and at the end of treatment  visit.   A total of six (6) 10 mL EDTA 
tubes  of blood will be collected at each time point.   The samples will be kept at 
room temperature and transported to Dr. Triozzi’s lab within 2 hours  of collection 
for further processing.  
6.3 Treatment Administration  
 
 
REGIMEN DESCRIPTION  
 
Agent   
Premedications  
  
Dose   
Route   
Schedule  Cycle 
Length  
Pembrolizumab   200 mg   30-minute IV 
infusion  Day 1  
21 days  Paclitaxel  Premedicate with  
ondansetron 8 
mg IV  or po , 
dexamethasone 10 mg IV or po, 
diphenhydramine 80 mg/m2 60-minute IV 
infusion  Days 1  
and 8 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 20 of 85 25 mg IV  or po , 
and ranitidine  
50mg IV  or po 
(or equivalent H2 
blocker ) 30-60 
minutes pre-
treatment .* 
*Premedications may b e substituted according to institutional guidelines.   
 
On day 1 of each cycle, pembrolizumab is to be given first, prior to the 
premedications and then followed by  paclitaxel.  
 Patients will be observed for 60 minutes after completion of chemotherapy , while 
in the treatment phase.  Patients receiving pembroliz umab alone in the 
maintenance phase need not have extended monitoring unless clinically indicated.   Vitals signs (blood pressure, heart rate, respiratory rate, oxygenation, and 
temperature) will be checked every hour while receiving treatment and prior to  
discharge from the treatment area.    
Trial treatment should be administered per the schedule above after  all 
procedures/assessments have been completed as detailed on t he Trial Flow Chart 
(Section 6.1).  Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.  
 
All trial treatments will be administered on an outpatient basis.  
  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 21 of 85  
6.4 General Concomitant Medication and Supportive Care 
Guidelines  
 
Medications or vaccinations specificall y prohibited in the exclusion criteria are not 
allowed during the ongoing trial.  If there is a clinical indication for one of these or other medications or vaccinations specifically prohibited during the trial, 
discontinuation from trial therapy or vaccination may be required.  The investigator 
should discuss any questions regarding this with the Merck Clinical team .  The final 
decision on any supportive therapy or vaccination rests with the investigator and/or 
the subject's primary physician.  
  6.4.1 Acceptable Concomitant Medications  
 
All treatments that the investigator considers necessary for a subject’s welfare may be administered at the discretion of the investigator in keeping with the community 
standards of medical care.  All concomitant medicat ion will be recorded on the 
case report form including all prescription, over -the-counter (OTC), herbal 
supplements, and IV medications and fluids.  If changes occur during the trial period, documentation of drug dosage, frequency, route, and date may also be 
included on the CRF.  
 
All concomitant medications received within 28 days before the first dose of trial 
treatment and 30 days after the last dose of trial treatment should be recorded.  
Concomitant medications administered after 30 days after the last  dose of trial 
treatment should be recorded for SAEs and ECIs as defined in Section 9.0.  
6.4.2 Prohibited Concomitant Medications  
 Subjects are prohibited from receiving the following therapies during the Screening 
and Treatment Phase (including retreatment for post -complete response relapse) 
of this trial:  
 
• Antineoplastic systemic chemotherapy or biological therapy  
• Immunotherapy not specified in this protocol  
• Chemotherapy not specified in this protocol  
• Investigational agents other than pembroliz umab 
• Radiation therapy  
o Note:  Radiation therapy to a symptomatic solitary lesion or to the brain 
may be allowed at the investigator’s discretion.   
• Live vaccines within 30 days prior to the first dose of trial treatment and while 
participating in the trial.   Examples of live vaccines include, but are not limited 
to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, 
rabies, BCG, and typhoid vaccine.  
• Systemic glucocorticoids for any purpose other than to modulate symptoms 
from an event  of clinical interest of suspected immunologic etiology.  The use 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 22 of 85 of physiologic doses of corticosteroids may be approved after consultation with 
the Sponsor.  
 Subjects who, in the assessment by the investigator, require the use of any of the 
aforementioned treatments for clinical  management should be removed from the 
trial.  Subjects may receive other medications that the investigator deems to be 
medically necessary.  
 
The Exclusion Criteria describes other medications which are prohibited in this 
trial. 
 There are no prohibited therapies during the Post -Treatment Follow -up Phase.  
6.4.3 Supportive Care Guidelines  
 
Subjects should receive appropriate supportive care measures as deemed 
necessary by the treating investigator.  Suggested supportive care measures  for 
the management of adverse events with potential immunologic etiology are outlined below and in Section 7.1. Where appropriate, these guidelines include the 
use of oral or intravenous treatment with corticosteroids as well as additional anti -
inflammato ry agents if symptoms do not improve with administration of 
corticosteroids.   Note that several courses of steroid tapering may be necessary 
as symptoms may worsen when the steroid dose is decreased. For each disorder, 
attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care. The 
treatment guidelines are intended to be applied when the investigator determines 
the events to be related to pembrolizumab.  
 
Note:  if after the evaluation the event is determined not to be related, the 
investigator is instructed to follow the ECI reporting guidance but does not need to follow the treatment guidance (as outlined in the ECI guidance document). Refer 
to Section 7.0 for dose modification.  
 
• Pneumonitis:  
The following AE terms, if considered ≥ G rade 2, are considered ECIs and  
should be reported to the Sponsor  within 24 hours of the event:  
– Pneumonitis  
– Interstitial lung disease  
– Acute interstitial pneumonitis  
 
If symptoms indicate possible new or worsening cardiac abnormalities additional 
testing and/or a cardiology  consultation should be considered.  All attempts should 
be made to rule out other causes such as metastatic disease, bacterial or viral 
infection. It  is important that patients with a suspected diagnosis of 
pneumonitis be managed as per the guidance  below until treatment -related 
pneumonitis is excluded. Treatment of both a potential infectious etiology 
and pneumonitis in parallel may be warranted. Managem ent of the treatment 
of suspected pneumonitis with steroid treatment should not be delayed for 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 23 of 85 a therapeutic trial of antibiotics. If an alternative diagnosis is established, the 
patient does not require management as below; however the AE  
should be repor ted regardless of etiology.  
 
o For Grade 2 events:  
– Hold pembrolizumab.  
– Consider pulmonary consultation with bronchoscopy and biopsy/BAL.  
– Consider ID consult . 
– Conduct an in person evaluation approximately twice per week . 
– Consider frequent Chest X -ray as part of monitoring.  
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg/day 
prednisone or equivalent. When symptoms improve to Grade 1 or less, 
steroid taper should be started and continued over no less than 4  weeks.  
– Permanently disc ontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
– Second episode of pneumonitis –  discontinue pembrolizumab if upon re -
challenge the patient develops  a second episode of Grade 2 or higher 
pneumonitis.  
 
o For Grade 3- 4 events:   
– Discontinue pembrolizumab.  
– Hospitalize patient . 
– Bronchoscopy with biopsy and/or BAL is recommended.  
– Immediately treat with intravenous steroids (methylprednisolone 125 mg 
IV). When symptoms  improve to Grade 1 or less, a high dose oral steroid 
(prednisone 1 to 2 mg/kg once per day or  dexamethasone 4 mg every 4 
hours) taper should be started and continued over no less than 4 weeks.  
– If IV steroids followed by high dose oral steroids does not reduce initial 
symptoms within 48 to 72 hours, treat with additional anti -inflammatory 
measures. Discontinue additional anti -inflammatory  measures upon 
symptom relief and initiate a prolonged steroid taper over 45 to 60 days. If 
symptoms  worsen during steroid reduction, initiate a retapering of steroids 
starting at a higher dose of 80 or 100  mg followed by a more prolonged 
taper and administer additional anti -inflammatory measures, as  needed  
– Add prophylactic antibiotics for opportunistic infections.  
. 
 
• Diarrhea/Colitis :  
Subjects should be carefully monitored for signs and symptoms of enterocolitis 
(such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) 
and of bowel perforation (such as peritoneal signs and ileus).   
 
The following AE terms, if  considered ≥ Grade 2 or resulting in dose modification 
or use of systemic steroids  to treat the AE, are considered ECIs and should be 
reported to the Sponsor within 24 hours of the event:  
– Colitis  
– Colitis microscopic  
– Enterocolitis  
– Enterocolitis hem orrhagic  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 24 of 85 – Gastrointestinal perforation 
– Intestinal obstruction  
– Necrotizing colitis  
– Diarrhea  
 
All attempts should be made to rule out other causes such as metastatic disease, 
bacterial or parasitic infection,  viral gastroenteritis, or the first manife station of an 
inflammatory bowel disease by examination for stool  leukocytes, stool cultures, a 
Clostridium difficile titer and endoscopy. However the AE should be reported  
regardless of etiology.  
 
o For Grade 2 events:  
– Hold pembrolizumab.  
– Symptomatic Treatment  
– For Grade 2 diarrhea that persists for greater than 3 days, and for 
diarrhea with blood and/or mucus,  consider GI consultation and endoscopy 
to confirm or rule out colitis  
– Administer oral corticosteroids (prednisone 1- 2 mg/kg QD or equivalent ) 
– When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less  than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
– If symptoms worsen or persist > 3 days treat as Grade 3  
 o For Grade 3- 4 events:   
– Hold pembrolizumab (if grade 3) or discontinue (if grade 4)  
– Rule out bowel perforation. Imaging with plain films or CT can be useful.  
– Recommend consultation with Gastroenterologist and confirmation 
biopsy with endoscopy.  
– Treat with intravenous steroids (methylprednisolone 125 mg) followed by 
high dose oral steroids  (prednisone 1 to 2 mg/kg once per day or 
dexamethasone 4 mg every 4 hours) When symptoms  improve t o Grade 1 
or less, steroid taper should be started and continued over no less than 4 weeks.  Taper over 6 to 8 weeks in patients with diffuse and severe 
ulceration and/or bleeding.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10  
mg or less of prednisone or  equivalent per day within 12 weeks.  
– If IV steroids followed by high dose oral steroids does not reduce initial 
symptoms within 48 to 72 hours, consider treatment with additional anti -
inflammatory measures.  Discontinue additional anti -inflammatory 
measures upon symptom relief and initiate a prolonged steroid taper over 
45 to 60 days. If symptoms worsen during steroid reduction, initiate a 
retapering of  steroids starting at a higher dose of 80 or 100 mg followed by 
a more prolon ged taper and administer additional anti -inflammatory 
measures as needed.   
 
 
 
• Endocrine:  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 25 of 85 The following AE terms, if considered ≥Grade 3 or if ≥Grade 2 and require 
holding/discontinuation/modification of pembrolizumab dosing, are considered 
ECIs and should be reported to the Sponsor within 24 hours of the event:  
– Adrenal insufficiency  
– Hyperthyroidism  
– Hypophysitis  
– Hypopituitarism  
– Hypothyroidism  
– Thyroid disorder  
– Thyroiditis  
 
o Hypophysitis:  
Grade 2- 4 events:  
– Hold pembrolizumab 
– Rule out infection and sepsis with appropriate cultures and imaging.  
– Monitor thyroid function or other hormonal level tests and serum 
chemistries more frequently until  returned to baseline values.  
– Pituitary gland imaging should be considered . 
– Treat with prednisone 40 mg p.o. or equivalent per day. When symptoms 
improve to Grade 1 or less,  steroid taper should be started and continued 
over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
– Permanently dis continue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
– Hypophysitis with clinically significant adrenal insufficiency and 
hypotension, dehydration, and electrolyte abnormalities (such as  
hyponatremia and hyperkalem ia) constitutes adrenal crisis.  
– Consultation with an endocrinologist may be considered.  
 
o Hyperthyroidism or Hypothyroidism :  
Thyroid disorders can occur at any  time during treatment. Monitor patients 
for changes in thyroid funct ion (at the start of treatment, periodically during 
treatment, and as indicated based on clinical evaluation) and for clinical 
signs and symptoms of thyroid disorders.  
 Grade 2 hyperthyroidism events (and Grade 2- 4 hypothyroidism):  
– Monitor thyroid function or other hormonal level tests and serum 
chemistries more frequently until returned to baseline values.  
– Thyroid hormone and/or steroid replacement therapy to manage adrenal 
insufficiency.  
– Therapy with pembrolizumab can be continued while treatm ent for the 
thyroid disorder is instituted.  
– In hyperthyroidism, non- selective beta- blockers (e.g. propranolol) are 
suggested as initial therapy.  
– In hypothyroidism, thyroid hormone replacement therapy is indicated per 
standard of care.  
    – Consultation with an endocrinologist may be considered.  
 
Grade 3/4  hyperthyroidism events:  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 26 of 85 – Hold pembrolizumab (grade 3) or discontinue (grade 4) . 
– Rule out infection and sepsis with appropriate cultures and imaging.  
– Treat with an initial dose of methylprednisolone 1 to 2 mg/kg 
intravenously followed by oral  prednisone 1 to 2 mg/kg per day. When 
symptoms improve to Grade 1 or less, steroid taper should be  started and 
continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
 
o Type 1 diabetes mellitus (new onset) and ≥ Grade 3 Hyperglycemia  
 
The follow ing AE terms are considered ECIs and should be reported to the 
Sponsor within 24 hours of the event:  
– Type I diabetes mellitus (T1DM), if new onset, including diabetic 
ketoacidosis (DKA)  
– Grade 3 or higher hyperglycemia, if associated with ketosis (ketonuria) 
or metabolic acidosis (DKA).  
 
Immune- mediated diabetes may present as new onset of Type 1 diabetes 
or an abrupt worsening of preexisting diabetes associated with laboratorial 
evidence of beta cell failure. All attempts should be made to rule out other 
causes such as type 2 diabetes mellitus (T2DM), T2DM decompensation, 
steroid- induced diabetes,  physiologic stress -induced diabetes, or poorly 
controlled pre- existing diabetes (either T1DM or T2DM), but  events 
meeting the above criteria should be reported  as ECIs regardless of 
etiology. The patients may present  with hyperglycemia (abrupt onset or 
abrupt  decompensation) with clinical evidence of diabetic ketoacidosis or 
laboratory evidence of insulin deficiency, such as ketonuria, laboratory 
evidence of met abolic acidosis, or low  or undetected c -peptide.  
 
T1DM should be immediately treated with insulin.  
T1DM or Grade 3- 4 Hyperglycemia events:  
- Hold pembrolizumab for new onset Type 1 diabetes mellitus or Grade 3 -
4 hyperglycemia associated with evidence of beta cell failure, and resume 
pembrolizumab when patients are clinically and metabolically stable.  
- Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3- 4 hyperglycemia associated with metabolic acidosis or 
ketonuria.  
- Evaluate patients with serum glucose and a metabolic panel, urine 
ketones, glycosylated hemoglobin,  and C -peptide.  
- Consultation with an Endocrinologist is recommended.  
- Consider local testing for islet cell antibodies and antibodies to GAD, IA -
2, ZnT8, and insulin may be obtained.  
 
 
• Hepatic:  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 27 of 85 The following AE terms, if considered ≥ Grade 2 or greater (or any grade with 
dose modification or use of  systemic steroids to treat the AE), are considered 
ECIs and should be reported to the Sponsor within 24 hour s of the event:  
– Autoimmune hepatitis  
– Hepatitis  
– Transaminase elevations  
All attempts should be made to rule out other causes such as metastatic disease, 
infection or other hepatic  diseases. However the AE should be reported 
regardless of etiology.  
 
In addition, the event must be reported as a Drug Induced Liver Injury (DILI) ECI, 
if the patient meets the laboratory criteria for potential DILI defined as:  
- An elevated alanine transaminase (ALT) or aspartate transaminase (AST) lab 
value that is greater than or equal to three times (3X) the upper limit of normal 
(ULN) and   
- An elevated total bilirubin lab value that is greater than or equal to two times 
(2X) ULN and  
- At the same time, an alkaline phosphatase (ALP) lab value that is less than 2X 
ULN,  
- As a result of within- protocol -specific testing or unscheduled testing.  
 
o Grade 2 events:  
– Hold pembrolizumab when AST or ALT >3.0 to 5.0 times ULN and/or 
total bilirubin >1.5 to 3.0 times  ULN.  
– Monitor liver function tests more frequently until returned to baseline 
values (consider weekly).  
– Treat with 0.5 -1 mg/kg/day methylprednisolone or oral equivalent and 
when LFT returns to grade 1 or baseline, taper steroids over at least 1 
month, consider prophylactic antibiotics for  opportunistic infections, and 
resume pembrolizumab per protocol  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
– Permanently discontinue pembrolizumab for patients with liver 
metastasis who beg in treatment with  Grade 2 elevation of AST or ALT, 
and AST or ALT increases ≥50% relative to baseline and lasts ≥1  week.  
 
o Grade 3 events:  
– Discontinue pembrolizumab when AST or ALT >5.0 times ULN and/or 
total bilirubin >3.0 times  ULN.  
 – Consider appropri ate consultation and liver biopsy to establish etiology 
of hepatic injury, if necessary  
– Treat with high -dose intravenous glucocorticosteroids for 24 to 48 
hours. When symptoms improve to  Grade 1 or less, a steroid taper with 
dexamethasone 4 mg every 4 hours or prednisone at 1 to 2 mg/kg should 
be started and continued over no less than 4 weeks.  
– If serum transaminase levels do not decrease 48 hours after initiation of 
systemic steroids, oral  mycophenolate mofetil 500 mg every 12 hours 
may be given. Infli ximab is not recommended due to  its potential for 
hepatotoxicity.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 28 of 85  
o Grade 4 events:  
– Permanently discontinue pembrolizumab 
– Manage patient as per Grade 3 above  
 
• Renal : 
 
The following AEs if ≥ Grade 2 are considered ECIs and should be reported to the 
Sponsor within 24 hours of  the event:  
– Nephritis  
– Nephritis autoimmune  
– Renal failure  
– Renal failure acute   
 
All attempts should be made to rule out other causes such as obstructive uropathy, 
progression of disease, or  injury due to other chemotherapy agents. A renal 
consultation is recommended. However the AE should be reported regardless of 
etiology.  
 
o Grade 2 events:  
– Hold pembrolizumab 
– Treatment with prednisone 1- 2 mg/kg p.o. daily.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
 
o Grade 3- 4 events:  
– Discontinue pembrolizumab  
– Renal consultation with consideration of ultrasound and/or biopsy as 
appropriate  
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone 
IV or equivalent once per  day. When symptoms improve to Grade 1 or less, 
steroid taper should be started and continued over no less than 4 weeks.  
 
• Hematologic:  
 
The following AE term, if considered Grade ≥3 or requiring dose modification or 
use of systemic steroids to  treat the AE, are considered an ECI and should be 
reported to the Sponsor within 24 hours of the event:  
– Autoimmune hemolytic anemia  
– Aplastic anemia 
– Disseminate d Intravascular Coagulation (DIC)  
– Haemolytic Uraemic Syndrome (HUS)  
– Idiopathic (or immune) Thrombocytopenia Purpura (ITP)  
– Thrombotic Thrombocytopenic Purpura (TTP)  
– Any Grade 4 anemia regardless of underlying mechanism  
 
All attempts should be made t o rule out other causes such as metastases, sepsis 
and/or infection. Relevant  diagnostic studies such as peripheral blood smear, 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 29 of 85 reticulocyte count, LDH, haptoglobin, bone marrow biopsy  or Coomb’s test, etc., 
should be considered to confirm the diagnosis. However the AE should be reported  
regardless of etiology.  
 
o Grade 2 events:  
– Hold pembrolizumab 
– Prednisone 1 -2 mg/kg daily may be indicated  
– Consider Hematology consultation.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
o Grade 3 events:  
– Hematology consultation 
– Hold pembrolizumab.  Discontinuation should be considered as per 
specific protocol guidance.  
– Treat with methylprednisolone 125 mg iv or prednisone 1- 2 mg/kg p.o. 
(or equivalent) as appropriate  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
o Grade 4 events:  
– Hematology consultation 
– Discontinue pembrolizumab .  
– Treat with methylprednisolone 125 mg iv or prednisone 1- 2 mg/kg p.o. 
(or equivalent) as appropriate  
 
 
• Neurologic :   
 
The following AE terms, regardless of grade, are considered ECIs and should be 
reported to the Sponsor  within 24 hours of the event:  
– Autoimmune neuropathy  
– Demyelinating polyneuropathy  
– Guillain -Barre syndrome 
– Myasthenic syndrome  
All attempts should be made to rule out other causes such as metastatic disease, 
other medications or infectious  causes. However the AE should be reported 
regardless of etiology.  
o Grade 2 events:  
– Consider withholding pembrolizumab.  
– Consider treatment with prednisone 1 -2 mg/kg p.o. daily as appropriate  
– Consider Neurology consultation. Consider biopsy for confirmation of 
diagnosis.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
o Grade 3 and 4 events:  
– Discontinue pembrolizumab  
– Obtain neurology consultation. Consider biopsy for confirmation of 
diagnosis  
– Treat with  systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone 
or equivalent once per day. If  condition worsens consider IVIG or other 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 30 of 85 immunosuppressive therapies as per local guidelines .  When symptoms 
improve to Grade 1 or less, steroid taper should be s tarted and continued 
over no less than 4  weeks.  
 
• Skin : 
 
Rash and Pruritus  
The following AEs should be considered as ECIs, if ≥ Grade 3 and should be 
reported to the Sponsor within 24 hours of the event:  
– Pruritus  
– Rash  
– In addition to CTCAE Grade 3 rash, any rash that is considered clinically 
significant, in the physician's  judgment, should be treated as an ECI. Clinical 
significance is left to the physician to determine, and could possibly include rashes 
such as the following:  
- rash with a duration > 2 weeks; OR  
- rash that is >10% body surface area; OR  
- rash that causes significant discomfort not relieved by topical medication or 
temporary cessation of study drug.  
 
Other Skin ECIs  
The following AEs should always be reported as ECIs, regardless of grade, and 
should be reported to the  Sponsor within 24 hours of the event:  
– Dermatitis exfoliative  
– Erythema multiforme  
– Steven’s Johnson syndrome  
– Toxic epidermal necrolysis  
 
o Grade 2 events:  
– Symptomatic treatment should be given such as topical 
glucocorticosteroids (e.g., betamethasone 0.1% cream or hydrocortisone 
1%) or urea -containing creams in combination with oral anti -pruritics  (e.g., 
diphenhydramine HCl or hydroxyzine HCl).  
– Treatment with oral steroi ds is at physician’s discretion.  
o Grade 3 events:  
– Hold pembrolizumab.  
– Consider Dermatology Consultation and biopsy for confirmation of 
diagnosis.  
– Treatment with oral steroids is recommended, starting with 1 mg/kg 
prednisone or equivalent once per  day or dexamethasone 4 mg four times 
orally  daily. When symptoms improve to Grade 1 or less,  
steroid taper should be started and continued over no less than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of prednisone or  equivalent per day within 12 weeks.  
o Grade 4 events:  
– Permanently discontinue pembrolizumab.  
– Dermatology consultation and consideration of biopsy and clinical 
dermatology photograph.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 31 of 85 – Initiate steroids at 1 to 2 mg/kg prednisone or equivalent. When 
symptoms improve to Grade 1 or  less, steroid taper should be started and 
continued over no less than 4 weeks  
• Ocular : 
The following AE terms, if considered Grade ≥2 or requiring dose modification or 
use of systemic steroids to treat the AE, is considered an ECI and should be 
reported to the Sponsor within 24 hours of the event:  
– Uveitis  
– Iritis 
All attempts should be made to rule out other causes such as metastatic disease, infection or other ocular  disease (e.g. glaucoma or cataracts). However the AE 
should be reported regardless of etiology.  
 
o Grade 2 events:  
– Evaluation by an ophthalmologist is strongly recommended.  
– Treat with topical steroids such as 1% prednisolone acetate suspension 
and iridocyclitics.  
– Discontinue pembrolizumab as per protocol if symptoms persist despite 
treatment with topical  immunosuppressive therapy.  
o Grade 3 events:  
– Evaluation by an ophthalmologist is strongly recommended  
– Hold pembrolizumab and consider permanent discontinuation as per  
specific protocol guidance.  
– Treat with systemic corticosteroids such as  prednisone at a dose of 1 to  
2 mg/kg per day. When  symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 
mg or less of pre dnisone or  equivalent per day within 12 weeks.  
o Grade 4 events:  
– Evaluation by an ophthalmologist is strongly recommended  
– Permanently discontinue pembrolizumab.  
– Treat with corticosteroids as per Grade 3 above  
 
• Management of Infusion Reactions : Signs and symptoms usually develop 
during or shortly after drug infusion and generally resolve completely within 24 
hours of completion of infusion.  
 
 
 
Table 4 below  shows treatment guidelines for subjects who experience an infusion 
reaction associated with administration of pembrolizumab (MK -3475).  
 
Table 4 Infusion Reaction Treatment Guidelines  
 
NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
Grade 1  Increase monitoring of vital 
signs as medically indicated None  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 32 of 85 NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  until the subject is deemed 
medically stable in the opinion 
of the investigator.  
Grade 2  
Requires infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for < =24 hrs  Stop Infusion and monitor 
symptoms.  
Additional appropriate medical therapy may include but is not 
limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Increase monitoring of vital 
signs as medically indicated 
until the subject is deemed 
medically stable in the opinion 
of the investigator.  
If symptoms resolve within 
one hour of stopping drug 
infusion, the infusion may be 
restarted at 50% of the 
original infusion rate (e.g., 
from 100 mL/hr to 50 mL/hr).  
Otherwise dosing will be held 
until symptoms resolve and 
the subject should be 
premedicated for the next 
scheduled dose.  
Subjects who develop Grade 2 toxicity despite 
adequate premedication 
should be permanently 
discontinued from further 
trial treatme nt 
administration.  Subject may be premedicated 
1.5h (± 30 minutes) prior to infusion of pembrolizumab (MK -
3475) with:  
 
Diphenhydramine 50 mg po (or 
equivalent dose of 
antihistamine).  
 
Acetaminophen 500- 1000 mg 
po (or equivalent dose of 
antipyretic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusi on); 
recurrence of symptoms 
following initial improvement; 
hospitalization indicated for 
other clinical sequelae (e.g., Stop Infusion.  
Additional appropriate medical 
therapy may include but is not 
limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  No subsequent dosing  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 33 of 85 NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
renal impairment, pulmonary 
infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Pressors  
Corticosteroids  
Epinephrine 
 
Increase monitoring of vital 
signs as medically indicated 
until the subject is deemed 
medically stable in the opinion 
of the investigator.  
Hospitalization may be 
indicated.  
Subject is permanently 
discontinued from further 
trial treatment 
administration.  
Appropriate resuscitation equipment should be available in the room and a physician readily 
available during the period of drug administration.  
 
 
6.5 Other Considerations 
  6.5.1 Contraception  
Pembrolizumab may have adverse effects on a fetus in utero.  
Furthermore, it is not known if pembrolizumab has  transient adverse effects 
on the composition of sperm.  Non- pregnant, non- breast -feeding women 
may be enrolled if they are willing to use 2 methods of birth control or are 
considered highly unlikely to conceive.  Highly unlikely to conceive is 
defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is 
≥45 years of age and has not had menses for greater than 1 year will be 
considered postmenopausal), or 3) not heterosexually active for the 
duration of the study.  The two birth control methods  can be either two 
barrier methods or a barrier method plus a hormonal method to prevent 
pregnancy. Subjects should start using birth control from study Visit 1 throughout the study period up to 120 days after the last dose of study 
therapy.  
 
The following are considered adequate barrier methods of contraception: 
diaphragm, condom (by the partner), copper intrauterine device, sponge, 
or spermicide.  Appropriate hormonal contraceptives will include any 
registered and marketed contraceptive agent that contai ns an estrogen 
and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).  
 
Subjects should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occu r during 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 34 of 85 the study.  In order to participate in the study they must adhere to the 
contraception requirement (described above) for the duration of  the study 
and during the follow -up period defined in section 7.2.2- Reporting of 
Pregnancy and Lactation to the Sponsor and to Merck .  If there is any 
question that a subject will not reliably comply with the requirements for 
contraception, that subject should not be entered into the study.  
6.5.2 Use in Pregnancy  
If a subject inadvertently becomes pregnant while on treatment with pembrolizumab, the subject will immediately be removed from the study.  
The site will contact the subject at least monthly and document the 
subject’s stat us until the pregnancy has been completed or terminated.  
The outcome of the pregnancy will be reported to the Sponsor and to Merck without delay and within 24 hours to the Sponsor and within 2 working days 
to Merck if the outcome is a serious adverse experience (e.g., death, 
abortion, congenital anomaly, or other disabling or life -threatening 
complication to the mother or newborn).   
 
The study investigator will make every effort to obtain permission to follow 
the outcome of the pregnancy and report the condition of the fetus or 
newborn to the Sponsor.   If a male subject impregnates his female partner 
the study personnel at the site must be informed immediately and the 
pregnancy reported to the Sponsor and to Merck and followed as described 
above and in Section 7.2.2.  
6.5.3 Use in Nursing Women  
It is unknown whether pembrolizumab is excreted in human milk.  Since 
many drugs are excreted in human milk, and because of the potential for 
serious adverse reactions in the nursing infant, subjects who are breast -
feeding are not eligible for enrollment.  
6.6 Duration of Therapy 
 
TREATMENT PHASE : 
 
In the absence of treatment delays due to adverse events, treatment  with the 
combination of paclitaxel and pembrolizumab may continue for  8 cycles or until 
one of the following criteria applies:  
 
• Confirmed radiographic disease progression (a subject may be granted an 
exception to continue on treatment with confirmed radiographic progression if 
clinically stable or clinically improved) , 
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Confirmed positive serum pregnancy test,  
• Noncompliance with trial treatment or procedure requirements,  
• The patient is lost to follow -up, 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 35 of 85 • Patient /legal representative withdraws consent , or 
• General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the treating physician.  
 
When a subject discontinues/withdraws prior to trial completion, all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  
Any adverse events which are present at the time of discontinuation/withdrawal should 
be followed in accordance with the safety requirements outlined in Sect ion 9.0.   
 
MAINTENANCE PHASE : 
 
In the absence of treatment delays due to adverse events, treatment with pembrolizumab may continue for 18 months or until one of the following criteria 
applies:  
 
• Confirmed radiographic disease progression (a subject may be granted an 
exception to continue on treatment with confirmed radiographic progression if 
clinically stable or clinically improved),  
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Confirmed positive serum pregnancy test,  
• Noncompliance with trial treatment or procedure requirements,  
• The patient is lost to follow -up, 
• Patient/legal representative withdraws consent, or  
• General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the treating physician.  
 
Patients who remain on pembrolizumab in the maintenance phase will be seen every 21 days, with imaging every 3 months (+/ - 10 days) for up to 18 months.  
 
 
6.7 Post-treatment Visits 
  6.7.1 Safety Follow -up Visit (End-of -treatment visit)  
 
The mandatory Safety Follow -Up Visit should be conducted within  30 days after 
the last dose of trial treatment or before the initiation of a new anti -cancer 
treatment, whichever comes first.  All AEs that oc cur prior to the Safety Follow -Up 
Visit should be recorded.  Subjects with an AE of Grade > 1 will be followed until 
the resolution of the AE to Grade 0 -1 or until the beginning of a new anti -neoplastic 
therapy, whichever occurs first.  SAEs that occur wit hin 90 days of the end of 
treatment or before initiation of a new anti -cancer treatment should also be 
followed and recorded.   
 
If stable disease or partial or complete response  noted at this visit , the patient will 
have the option of remaining on pembrol izumab alone for an additional 18 months,  
in the maintenance phase as described above.    
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 36 of 85  
6.7.2  Follow Up 
 
Patients who do not have progressive disease but who decline maintenance  
pembrolizumab will be followed every 3 months (+/ - 10 days) for up to 18 months  
after the end of treatment.  These patients will have scans every 3 months (+/ - 10  
days).  All patients will be continued to followed for survival status.   
 
.  Patients who discontinue t reatment for reasons  other than progressive disease 
should be assessed every 3 months  (± 10 days) by radiologic imaging to monitor 
disease status. Every effort should be made to collect information regarding 
disease status until the start of new anti -neoplastic therapy, disease progression, 
death, end of the study or lost to follow up.  Information regarding post -study anti -
neoplastic treatment will be collected if new treatment is initiated.  
  
All patients will have survival status assessed every 3 months  until death or 
withdrawal of consent .  . 
7.0 Dosing Delays/Dose Modifications  
 
 7.1  Pembrolizumab  
 
Adverse events (both non- serious and serious) a ssociated with pembrolizumab exposure 
may represent an immunologic etiology.  These adverse events may occur shortly after 
the first dose or several months after the last dose of treatment. Pembrolizumab must  be 
withheld  for drug-related  toxicities  and severe or life- threatening AEs as per the table 
below. Toxicity must return to Grade 0 -1 by day 1 of each cycle.  Dosing interruptions are 
permitted in the case of medical / surgic al events or logistical reasons  not related to study 
therapy (e.g., elect ive surgery, unrelated medical events, patient vacation, and/or 
holidays). Subjects should be placed back on study therapy within 3 weeks of the 
scheduled interruption, unless otherwise discussed with the Sponsor. The reason for 
interruption should be documented in the patient's study record.  
  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 37 of 85 Dose Modification and Toxicity Management Guidelines for Immune- related AEs 
Associated with Pembrolizumab  
General instructions:  
1. Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 weeks.  
2. For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to 
Grade 1 or 0 and corticosteroid has been tapered. Pembrolizumab should be permanently discontinued if AE does not 
resolve within 12 weeks of last dose or corticosteroids cannot be reduced to ≤10 mg prednisone or equivalent per day 
within 12 weeks.  
3. For severe and life-threatening irAEs, IV corticosteroid should be initiated first followed by oral steroid. O ther 
immunosuppressive treatment should be initiated if irAEs cannot be controlled by corticosteroids.  
 
Immune -related AEs  Toxicity grade 
or conditions 
(CTCAEv4.0)  Action taken to 
pembrolizumab  irAE management 
with corticosteroid 
and/or other 
therapies  Monitor and follow -up  
Pneumonitis  Grade 2  Withhold  • Administer 
corticosteroids 
(initial dose of 1-2 mg/kg prednisone 
or equivalent) 
followed by taper  
 • Monitor participants for 
signs and symptoms of 
pneumonitis  
• Evaluate participants with 
suspected pneumonitis with 
radiographic imaging and 
initiate corticosteroid 
treatment  
• Add prophylactic antibiotics 
for opportunistic infections  Grade 3 or 4, or 
recurrent Grade 
2 Permanently 
discontinue  
Diarrhea / Colitis  Grade 2 or 3  Withhold  • Administer 
corticosteroids 
(initial dose of 1-2 mg/kg prednisone 
or equivalent) 
followed by taper  
 • Monitor participants for 
signs and symptoms of 
enterocolitis (ie, diarrhea, abdominal pain, blood or 
mucus in stool with or 
without fever) and of bowel 
perforation (ie,  peritoneal 
signs and ileus).  
• Participants with ≥ Grade 2 
diarrhea suspecting colitis 
should consider GI 
consultation and performing 
endoscopy to rule out colitis.  
• Participants with 
diarrhea/colitis should be 
advised to drink liberal quantities of clear f luids.  If 
sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be 
substituted via IV infusion.  Grade 4  Permanently 
discontinue  
AST / ALT elevation or 
Increased bilirubin  Grade 2  Withhold  • Administer 
corticosteroids 
(initial dose  of 0.5 - 1 
mg/kg prednisone or 
equivalent) followed 
by taper  • Monitor with liver function tests 
(consider weekly or more 
frequently until liver enzyme 
value returned to baseline or is 
stable  
Grade 3 or 4  Permanently discontinue  • Administer 
corticosteroids  
(initial dose of 1- 2 
mg/kg prednisone or 
equivalent) followed 
by taper  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 38 of 85 Immune -related AEs  Toxicity grade 
or conditions 
(CTCAEv4.0)  Action taken to 
pembrolizumab  irAE management 
with corticosteroid and/or other 
therapies  Monitor and follow -up  
Type 1 diabetes mellitus 
(T1DM) or 
Hyperglycemia  
 Newly onset 
T1DM or  
Grade 3 or 4 hyperglycemia associated with 
evidence of β-
cell failure  Withhold  • Initiate insulin 
replacement 
therapy for participants with 
T1DM  
• Administer anti -
hyperglycemic in participants wi th 
hyperglycemia  
 • Monitor participants for 
hyperglycemia or other 
signs and symptoms of diabetes.  
Hypophysitis  Grade 2  Withhold  • Administer 
corticosteroids 
and initiate 
hormonal replacements as clinically 
indicated.   
 • Monitor for signs and 
symptoms of hypophysitis 
(including hypopituitarism 
and adrenal insufficiency)   Grade 3 or 4  Withhold or 
permanently 
discontinue1  
Hyperthyroidism  Grade 2  Continue  • Treat with non -
selective beta-blockers (eg, 
propranolol) or thionamides as appropriate  • Monitor for signs and 
symptoms of thyroid 
disorders.  
 Grade 3 or 4  Withhold or  
permanently 
discontinue1 
Hypothyroidism  Grade 2 -4 Continue  • Initiate thyroid 
replacement hormones (eg, 
levothyroxine or 
liothyroinine) per 
standard of care  • Monitor for signs and 
symptoms of thyroid 
disorders.  
 
Nephritis and Renal 
dysfunction Grade 2  Withhold  • Administer 
corticosteroids (prednisone 1- 2 
mg/kg or 
equivalent) 
followed by taper.  • Monitor changes of renal 
function  
 Grade 3 or 4  Permanently 
discontinue  
Myocarditis  Grade 1 or 2  Withhold  • Based on severity 
of AE administer 
corticosteroids  • Ensure adequate evaluation 
to confirm etiology and/or exclude other causes  
 Grade 3 or 4  Permanently 
discontinue  
All other immune -related 
AEs Intolerable/ 
persistent Grade 
2 Withhold  • Based on type 
and severity of AE administer corticosteroids  • Ensure adequate evaluation 
to confirm etiology and/or exclude other causes  
 Grade 3  Withhold or 
discontinue based on 
the type of event.  
Events that require discontinuation include 
and not limited to:  
Gullain-Barre 
Syndrome, 
encephalitis  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 39 of 85 Grade 4 or 
recurrent Grade 
3  Permanently 
discontinue  
1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.   
NOTE:  
For participants with Grade 3 or 4 immune-related endocrinopathy where withhold of pembrolizumab is required, 
pembrolizumab may be resumed when AE resolves to ≤ Grade 2 and is controlled with hormonal replacement therapy or 
achieved metabolic control (in case of T1DM).   
7.2   Paclitaxel  
 
On day of treatment  Paclitaxel Modification  
ANC < 1000  Hold paclitaxel for one week. If ANC >1000 the following week, treat at 80 
mg/m2.  If ANC still <1000, hold for another week and reduce all subsequent 
doses to 60 mg/m2.   
Platelet < 100,000  Hold paclitaxel for one week. If platelet > 100K at the following week, reduce 
paclitaxel to 60mg/m2 on next and all subsequent doses. If platelets remain 
<100K, drop paclitaxel  and continue with pembrolizumab alone.   
Febrile neutropenia  Hold paclitaxel until episode resolves to grade 1 or below.  For next cy cle, 
reduce paclitaxel  to 60 mg/ m2.  If recurs, drop paclitaxel and continue with 
pembrolizumab alone.   
Neurotoxicity (includin g 
peripheral neuropathy)  Hold pacli taxel until resolution to Grade 1 or below .  If recurs, or not resolved to 
< Grade 2 after having dose held for two weeks, then continue with 
pembrolizumab alone.   
Other Possibly -Related 
Grade 3 AEs If probably or possibly related to paclitaxel, hold paclitaxel until resolution to Grade ≤ 1. If it recurs to Grade 3 or greater, discontinue paclitaxel and continue 
with pembrolizumab alone.    
All Grade 4 AEs   All Grade 4 AEs possibly related to paclitaxel should result in discontinuation of 
paclitaxel  
 
Management of acute hypersensitivity  will be as per local institutional guidelines.   
Further therapy should be customized depending upon the clinical situation.  The clinical tolerance 
of the patient, the overall tumor response and the medical judgment of the investigator will determine if it is in the patient’s best interest to cont inue or discontinue treatment.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 40 of 85 8.0 Measurement of Effect  
8.1 Antitumor Effect  
 
Response and progression will be evaluated in this study using the Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1.36   While in the treatment 
phase, the pa tients will be reevaluated for response prior to cycle 4 , prior to cycle 
7, and at the end -of-treatment.   In addition to a baseline scan, confirmatory scans 
should also be obtained as per RECIST criteria following initial documentation of 
objective response.  
8.1.1  Definitions  
   
• Evaluable for toxici ty: All patients will be evaluable for toxicity from the time 
of their first treatment with pem brolizumab 
• Inevaluable for objective response: When no imaging/measurement is 
done at all  at a particular time point, the patient is not  evaluable (NE) at 
that t ime point.  
o If only a subset of lesion measurements are made at an 
assessment, usually the case is  also considered NE at that time 
point, unless  a convincing argument can be made that the  
contribution of the individual missing lesion(s)  would not change the  
assigned time point  response. This would most likely happen in the 
case of PD.  
• Measurable disease: Measurable lesions are defined as those that can be 
accurately measured in at least one  dimension (longest diameter in the 
plane of  measurement is to be recorded) with a minimum size of:   
o 10 mm by CT scan (CT scan slice thickness no greater than 5 mm; 
when CT scans have slice thickness >5 mm, the minimum size  
shoul d be twice the slice thickness);  
o 10 mm caliper measurement by clinical  exam (lesions which c annot 
be accurately  measured with calipers should be recorded  as non-
measurable).  
o 20 mm by chest X -ray. 
• Measurable lesions:  
o Malignant lymph nodes : To be considered pathologically enlarged  
and measurable, a lymph node must be  ≥15 mm in short axis when 
asses sed by CT scan (CT scan slice thickness is  recommended to 
be no greater than 5 mm).  At baseline and in follow -up, only the 
short  axis will be measured and followed.  
o Lytic bone lesions or mixed lytic -blastic  lesions with identifiable soft 
tissue  components that can be evaluated by crosssectional  imaging 
techniques such as CT or  MRI can be considered measurable if the  
soft tissue component meets the definition of measurability 
described above.  
o ‘Cystic lesions’ thought to represent cystic  metastases can be 
considered measurable if they meet the definition of measurability  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 41 of 85 described above. However, if non- cystic lesions are present in the 
same patient,  these are preferred for selection as  target lesions.  
• Non-measurable lesions : Non-measurable lesions are all other lesions,  
including small lesions (longest diameter  <10 mm or pathological lymph 
nodes with 10 to <15 mm short axis), as well as truly  non-measurable 
lesions. Lesions considered truly non- measurable include: leptomeningeal  
disease, ascites, pleural or pericardial effusion,  inflammatory breast 
disease, lymphangitic  involvement of skin or lung, abdominal  
masses/abdominal organomegaly identified by physical exam that is not 
measurable by  reproducible imaging techniques.  
o Lesions with prior local treatment, such  as those situated in a 
previously irradiated area or in an area subjected to other  loco-
regional therapy, are usually not  considered measurable unless 
there has  been demonstrated progression in the  lesion.  
• Target lesions : All measurable lesions up to a maximum  of two lesions per 
organ and five lesions in  total, representative of all involved organs,  should 
be identified as target lesions and recorded  and measured at baseline.  
o Target lesions should be selected on the basis of their size (lesions 
with t he longest  diameter) and be representative of all  involved 
organs, as well as their suitability  for reproducible repeated 
measurements.  
o All measurements should be recorded in  metric notation using 
calipers if clinically  assessed.  
o A sum of the diameters (longest for non -nodal  lesions, short axis for 
nodal lesions) for all  target lesions will be calculated and reported  
as the baseline sum diameters, which will be used as reference to 
further characterize any  objective tumor regression in the 
measurable dimens ion of the disease. If lymph nodes  are to be 
included in the sum, only the  short axis will contribute.  
o Lymph nodes identified as target lesions  should always have the 
actual short axis  measurement recorded even if the nodes  regress 
to below 10 mm on study.  When lymph nodes are included as target 
lesions,  the ‘sum’ of lesions may not be zero even if complete 
response criteria are met since a normal lymph node is defined as 
having  a short axis of <10 mm.  
o Target lesions that become ‘too small to  measure’:  While on study, 
all lesions (nodal  and non- nodal) recorded at baseline should have 
their actual measurements recorded  at each subsequent 
evaluation, even when very small. However, sometimes lesions or  
lymph nodes become so faint on a CT scan  that the radi ologist may 
not feel comfortable  assigning an exact measure and may report  
them as being ‘too small to measure’, in which case a default value 
of 5 mm should be assigned.  
o Lesions that  split or coalesce on treatment: When non- nodal lesions 
‘fragment’,  the longest diameters of the fragmented portions should 
be added together to  calculate the target lesion sum. Similarly,  as 
lesions coalesce, a plane between them may be maintained that 
would aid in obtaining maximal diameter measurements  of each 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 42 of 85 individual les ion. If the lesions  have truly coalesced such that they 
are no longer separable, the v ector of the longest diameter in this 
instance should be the maximal longest diameter for the ‘coalesced 
lesion’.  
• Non-target lesions: All lesions (or sites of disease) no t identified  as target 
lesions, including pathological lymph nodes and all non- measurable 
lesions, should be identified as non- target lesions and be recorded at 
baseline. Measurements of these  lesions are not required and they should 
be followed as ‘present’, ‘absent’ or in rare cases,  ‘unequivocal 
progression’.  
8.1.2  Methods for Evaluation of Measurable Disease  
  
The same method of assessment and the same technique should be used 
to characterize each identified and repo rted lesion at baseline and during 
follow -up. While either CT or MRI may be utilized, as per RECIST 1.1, CT 
is the preferred imaging technique in this study.  
8.1.3  Response Criteria  
 
• Complete Response (CR):  Disappearance of all target lesions . Any 
pathological lymph nodes (whether target o r non- target) must have 
reduction in short axis to <10 mm  
• Partial Response (PR):  At least a 30% decrease in the sum of diameters 
of target lesions, taking as reference the baseline sum of diameters  
• Progressive Disease (PD):  At least a 20% increase in the sum of diameters  
of target lesions, taking as reference the smallest sum on study (this may 
include the baseline sum). The sum must also demonstrate an absolute 
increase of at least 5 mm.  
• Stable Disease (SD):  Neither sufficient shrinkage to qualify for P R nor 
sufficient increase to qualify for PD . 
8.1.4  Evaluation of Non-Target Lesions  
 
• Complete Response (CR):  Disappearance of all non- target lesions and  
normalization of tumor marker levels. All  lymph nodes must be non-
pathological in size (<10 mm short axis).  
• Non-CR / Non -PD: Persistence of one or more non- target  lesion(s) and/or 
maintenance of tumor marker  levels above normal limits.  
• Progressive Disease (PD):  Unequivocal progression of existing non -target  
lesions.  
o When  patient has measurable disease: To achieve ‘unequivocal 
progression’ on the basis of the non- target disease, there must  be an 
overal l level of substantial worsening in non- target disease such that, 
even in presence of SD or PR in target disease,  the overall tumor 
burden has increased sufficiently to merit discontinuation of  therapy. A 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 43 of 85 modest ‘increase’ in the size of one or more non- target lesions is  
usually not sufficient to qualify for  unequivocal progression status.  
o When patient has only non- measurable  disease: There is no 
measurable disease  assessment to factor into the interpretation  of an 
increase in non -measurable disease burden. Because worsening in 
non-target  disease cannot be easily quantified, a useful  test that can be 
applied is to consider if the increase in overall disease bu rden based  
on change in non- measurable disease is  comparable in magnitude to 
the increase that would be required to declare PD for  measurable 
disease. Examples include an  increase in a pleural effusion from ‘trace’  
to ‘large’ or an increase in lymphangitic  disease from localized to 
widespread.  
• New lesions : The appearance of new malignant lesions  denotes disease 
progression.  
o The finding of a new lesion should be unequivocal (i.e., not attributable 
to differences in scanning technique, change in imaging modal ity or 
findings thought  to represent something other than tumor,  especially 
when the patient’s baseline lesions show partial or complete response).  
o If a new lesion is equivocal, for example because of its small size, 
continued therapy  and follow -up evaluat ion will clarify if it  represents 
truly new disease. If repeat  scans confirm there is definitely a new  
lesion, then progression should be declared  using the date of the initial 
scan.  
o A lesion identified on a follow -up study in an anatomical location that 
was not scanned  at baseline is considered a new lesion and disease 
progression.  
o It is sometimes reasonable to incorporate the  use of FDG -PET 
scanning to complement CT  in assessment of progression (particularly  
possible ‘new’ disease). New lesions on the basis of FDG -PET imaging 
can be identified  according to the following algorithm:  
 Negative FDG -PET at baseline, with a positive FDG -PET a t 
follow -up is PD based on a new lesion.  
 No FDG -PET at baseline and a positive FDG -PET at follow -up: 
• If the positive FDG -PET at follow -up corresponds to a 
new site of disease  confirmed by CT, this is PD.  
• If the positive FDG -PET at follow -up is not confirmed as 
a new site of disease on CT, additional follow -up CT 
scans are needed to determine if there is truly 
progression occurring at that site (if so, the date of PD 
will be the date of the initial abnormal FDG -PET scan).  
• If the positive FDG -PET at follow -up corresponds to a 
pre-existing site of  disease on CT that is not progressing 
on the basis of the anatomic  images, this is not PD.  
8.1.5  Evaluation of Best Overall Response  
 
Table 1 p rovides a summary of the overall response status  calculation at each time 
point for patie nts who have measurable disease at baseline.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 44 of 85  
Table 1. Overall response for patients with target (± non- target) disease  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
CR NE No PR 
PR Non-PD or not all evaluated  No PR 
SD Non-PD or not all evaluated  No SD 
Not all evaluate  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive 
Disease, NE = Inevaluable  
 
When patients have non- measurable (therefore non- target) disease only, Table 2 
should be used.  
 
Table 2. Overall response for patients with non- target disease  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/Non -PD No Non-CR/Non -PD1 
Not all evaluated  No NE 
Unequivocal PD  Yes or No  PD 
Any Yes PD 
CR = Complete Response, PD = Progressive Disease, NE = Inevaluable  
1 Non-CR / n on-PD is preferred over ‘Stable Disease’ for non -target disease since SD is 
incre asingly used as an endpoint for assessment of efficac y in some trials. To assign th is 
category when no lesions can be measured is not advised.  
 
8.1.6  Duration of Response  
 
Duration of overall response:  The duration of overall response is measured from 
the time measurement criteria are first met for CR/PR (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for progressive disease the smallest measurements recorded on study).  
 
The duration of overall complete response is measured from the time 
measurement criteria are first met for CR until the first date that recurrent disease 
is objectively documented.  
 
Duration of stable disease:  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the smallest 
measurements recorded since the treatment started.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 45 of 85 8.1.7  Survival Outcomes  
 
Progression- Free Survival is defined as the duration of time from the start of 
treatment to the time of progression , death, or date of last contact . 
 
Overall Survival is defined as the duration of time from the start of treatment to 
date of death or date of last contact . 
8.1.8  Response Review  
 
For trials where the response rate is the primary endpoint, it is strongly 
recommended that all responses be reviewed by an expert(s) independent of the 
study at the study’s completion.  Simultaneous review of the patients’ files and 
radiological images is  the best approach.  
9.0 Adverse Events List and Reporting Requirements  
9.1 Assessing and Recording Adverse Events  
 
An adverse event is defined as any untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product and which 
does not necessarily have to have a causal relationship with this treatment. An 
adverse event can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of a medicinal product or protocol -specified procedure, 
whether or not considered related to the medicinal product or protocol -specified 
procedure.  Any worsening (i.e., any clinically significant adverse change in 
frequency and/or int ensity) of a preexisting condition that is temporally associated 
with the use of the Merck’s product, is also an adverse event.  
 
Changes resulting from normal growth and development that do not vary 
significantly in frequency or severity from expected levels are not to be considered 
adverse events.  Examples of this may include, but are not limited to, teething, 
typical crying in infants and children and onset of menses or menopause occurring 
at a physiologically appropriate time.  
 Merck product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational 
(including placebo or active comparator medication) or marketed, manufactured 
by, licensed by, provided by or distributed by Mer ck for human use.  
 Adverse events may occur during the course of the use of Merck product in clinical 
trials or within the follow -up period specified by the protocol, or prescribed in 
clinical practice, from overdose (whether accidental or intentional), fr om abuse and 
from withdrawal.  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 46 of 85 Adverse events may also occur in screened subjects during any pre -allocation 
baseline period as a result of a protocol -specified intervention, including washout 
or discontinuation of usual therapy, diet, placebo treatment or a procedure.  
 
Progression of the cancer under study is not considered an adverse event unless 
it is considered to be drug related by the investigator.  
 
All adverse events will be recorded from the time the consent form is signed 
through 30 days following c essation of treatment and at each examination on the 
Adverse Event case report forms/worksheets. The reporting timeframe for adverse events meeting any serious criteria is described in section 9.5.  
 Adverse reactions considered expected for pembrolizumab include:  
 
System Organ Class  Adverse Event Term  
Blood and lymphatic system  disorders  Anemia  
Endocrine  disorders  Hyperthyroidism,  hypophysitis, 
hypopituitarism, hypothyroidism, 
secondary adrenal insufficiency, 
thyroid disorder  
Eye disorders  Uveitis  
Gast rointestinal disorders  Abdominal pain, colitis, constipation, 
diarrhea, nausea, pancreatitis, 
vomiting  
General disorders and administration 
site conditions  Asthenia, fatigue, peripheral edema, 
pyrexia  
Hepatobiliary disorders  Hepatitis  
Injury, poisoning and procedural 
complications  Infusion related reaction  
Metabolism and nutrition 
complications  Decreased appetite, diabetic 
ketoacidosis, hyponatremia, Type 1 
diabetes mellitus  
Musculoskeletal and connective 
tissue disorders  Arthralgia, back pain, myositi s 
Renal and urinary disorders  Nephritis  
Respiratory, thoracic and mediastinal 
disorders  Cough, dyspnea, pneumonitis  
Skin and subcutaneous tissue 
disorders  Pruritus, rash, severe skin reactions  
9.1.1  Serious Adverse Events  
 
A serious adverse event is any adverse event occurring at any dose or during any use of Merck’s product that:  
• Results in death;  
• Is life threatening;  
• Results in persistent or significant disability/incapacity;  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 47 of 85 • Results in or prolongs an existing inpatient hospitalization;  
• Is a congeni tal anomaly/birth defect;  
• Is a new cancer (that is not a condition of the study);  
• Is associated with an overdose;  
• Is another important medical event  
 
Refer to the table in section 9.1.4 below for additional details regarding 
each of the above criteria.  
 
In the pembrolizumab monotherapy trials, the most commonly reported 
DRSAEs (those that  occurred in 3 or more subjects overall in at least 1 
study) were pneumonitis (range of 0.7% to 1.3% of subjects); colitis (range 
of 0.3% to 1.1% of subjects), pyrexia (range of 0.3% to 0.5%  of subjects); 
diarrhea (range of 0.2% to 0.4%); hepatitis (0.7% of subjects); nausea, 
adrenal  insufficiency, hyponatremia , hyperthyroidism, hypophysitis, 
vomiting, and dyspnea (0.3% of subjects each); and dehydration, 
generalized edema,  hypothyroidism, renal failure acute, and pericardial 
effusion (0.2% of subjects each). The remaining DRSAEs occurred in 1 or 
2 subjects each per study.  
 
In the combination therapy trials, all DRSAEs were reported in 1 subject 
each. In P021, 8  subjects exp erienced DRSAEs; the DRSAEs were as 
follows: anemia, febrile neutropenia,  atrial fibrillation, colitis, pyrexia, 
hypersensitivity, alanine aminotransferase increased,  aspartate 
aminotransferase increased, drug eruption, rash, and urticaria. In P023, 2 
subjects experienced DRSAEs; 1 subject had an event of pneumonia and 
the other had an event of  tumor lysis syndrome.  
  9.1.2  Events of Clinical Interest  
 
Selected non- serious and serious adverse events are also known as 
Events of Clinical Interest (ECI) and must be recorded as such on the 
Adverse Event case report forms/worksheets and reported within 24 hours to the Sponsor and within 2 working days to Merck Global Safety. (Attn: 
Worldwide Product Safety; FAX 215 993- 1220)Events of clinical interest for 
this trial include:  
1.  an overdose of Merck product, as defined in Section 9.1.3 , that 
is not associated with clinical symptoms or abnormal laboratory 
results.  
2.  an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab 
value that is greater than or equal to 2X the upper limit of normal 
and, at the same time, an alkaline phosphatase lab value that is 
less than 2X the upper limit of normal, as determined by way of 
protocol -specified laboratory testing or unscheduled laboratory 
testing.*  
*Note:   These criteria are based upon available regulatory guidance 
documents. The purpose of the criteria is to specify a threshold of abnormal 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 48 of 85 hepatic tests that may require an additional evaluation for an underlying 
etiology.  The trial site guidance for assessment and follow up of these 
criteria can be found in the Investigator Trial File Binder (or equivalent).  
 Additional adverse events:  
 
A separate guidance document has been provided entitled “Event of 
Clinical Interest Guidance Document .” This document can be found in the 
Investigator Tr ial File Binder (or equivalent) and provides guidance 
regarding identification, evaluation and management of ECIs .   
 
ECIs (both non- serious and serious adverse event s) identified in this 
guidance document from the date of first dose through 90 days following 
cessation of treatment, or 30 days after the initiation of a new anticancer 
therapy, whichever is earlier, need to be reported within 24 hours to the 
Sponsor and within 2 working days to Merck Global Safety. (Attn: 
Worldwide Product Safety; FAX 215 993- 1220), regardless of attribution to 
study treatment, consistent with standard SAE reporting guidelines.  
 Subjects should be assessed for possible ECIs prior to each dose.  Lab 
results should be evaluated and subjects should be asked for signs and symptoms suggestive of an immune -related event.  Subjects who develop 
an ECI thought to be immune- related should have additional testing to rule 
out other etiologic causes.  If lab results or symptoms indicate a possible immune- related ECI, then additional testing should be performed to rule 
out other etiologic causes.  If no other cause is found, then it is assumed to be immune- related.  
 
9.1.3  Definition of an Overdose for Th is Protocol and Reporting 
of Overdose to the Sponsor and to Merck  
 
For purposes of this trial, an overdose of pembrolizumab will be defined as 
any dose of 1,000 mg or greater (≥5 times the indicated dose).  No specific 
information is available on the treat ment of overdose of pembrolizumab. 
Appropriate supportive treatment should be provided if clinically indicated. In the event of overdose, the subject should be observed closely for signs 
of toxicity.  Appropriate supportive treatment should be provided if clinically 
indicated.  
 If an adverse event(s) is associated with (“results from”) the overdose of a 
Merck product, the adverse event(s) is reported as a serious adverse 
event, even if no other seriousness criteria are met.  
 
If a dose of Merck’s product mee ting the protocol definition of overdose is 
taken without any associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non -serious Event of Clinical Interest 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 49 of 85 (ECI), using the terminology “accidental or intentional overdose without 
adverse effect.”  
 
All reports of overdose with and without an adverse event must be reported 
within 24 hours to the Sponsor and within 2 working days hours to Merck 
Global Safety. (Attn: Worldwide Product Safety; FAX 215 993 -1220)  
9.1.4  Merck Requ irements for Evaluating Adverse Events  
 
An investigator who is a qualified physician will evaluate all adverse events 
according to the NCI Common Terminology for Adverse Events (CTCAE), 
version 4.0. Any adverse event which changes CTCAE grade over the 
course of a given episode will have each change of grade recorded on the 
adverse event case report forms/worksheets.  
 
All adverse events regardless of CTCAE grade must also be evaluated for 
seriousness.  
 
An investigator who is a qualified physician, will evaluate all adverse events 
as to:  
V4.0 CTCAE 
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention 
not indicated.  
 Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate 
instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life -threatening; hospitalization or 
prolongation or hospitalization indicated; disabling; limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade 5  Death related to AE  
Seriousness  A serious adverse event is any adverse event occurring at any dose or during any use of Merck product that:  
 †Results in death ; or 
 †Is life threatening; or  places the subject, in the view of the investigator, at immediate risk of death from the event 
as it occurred (Note: This does not include an adverse event that, had it occurred in a more severe form, might have 
caused death.); or  
 †Results in a persiste nt or significant disability/incapacity  (substantial disruption of one’s ability to conduct 
normal life functions); or  
 †Results in or prolongs an existing inpatient hospitalization  (hospitalization is defined as an inpatient admission, 
regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: 
Hospitalization [including hospitalization for an elective procedure] for a preexisting condition which has not 
worsened does not constitute a serious adve rse event.); or  
 †Is a congenital anomaly/birth defect  (in offspring of subject taking the product regardless of time to diagnosis);or  
 Is a new cancer;  (that is not a condition of the study)  or 
 Is an overdose  (whether accidental or intentional).  Any adverse event associated with an overdose is considered a 
serious adverse event. An overdose that is not associated with an adverse event is considered a non- serious event of 
clinical interest and must be reported  within 24 hours.  
 Other important medical events  that may not result in death, not be life threatening, or not require hospitalization 
may be considered a serious adverse event when, based upon appropriate medical judgment, the event may jeopardize the s ubject and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and 
units  
Action taken  Did the adverse event cause the Merck product to be discontinued?  
Relationship 
to test drug  Did the Merck product cause the adverse event? The determination of the likelihood that the Merck product caused 
the adverse event will be provided by an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a 
medically qualified assessment of causality was done. This initialed document must be retained for the required 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 50 of 85 regulatory time frame. The criteria below are intended as ref erence guidelines to assist the investigator in assessing 
the likelihood of a relationship between the test drug and the adverse event based upon the available information.  
The following components are to be used to assess the relationship between the Merck product and the AE ; 
the greater the correlation with the components and their respective elements (in number and/or intensity), the more 
likely the Merck product caused the adverse event (AE):  
 Exposure  Is there evidence that the subject was actually e xposed to the Merck product such as: reliable history, 
acceptable compliance assessment (pill count, diary, etc.), expected pharmacologic effect, or 
measurement of drug/metabolite in bodily specimen?  
 Time 
Course Did the AE follow in a reasonable temporal sequence from administration of the Merck product?  
Is the time of onset of the AE compatible with a drug- induced effect (applies to trials with 
investigational medicinal product)?  
 Likely 
Cause  Is the AE not rea sonably explained by another etiology such as underlying disease, other 
drug(s)/vaccine(s), or other host or environmental factors  
 
Relationship  The following components are to be used to assess the relationship between the test drug and the AE: (continued)  
to Merck 
product  
(continued)  Dechallenge  Was the Merck product discontinued or dose/exposure/frequency reduced?  
If yes, did the AE resolve or improve?  
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.  
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the 
AE resolved/improved despite continuation of the Merck product; or (3) the trial is a single- dose drug 
trial); or (4) Merck product(s) is/are only used one time.)  
 Rechallenge  Was the subject re -exposed to the Merck product in this study?  
If yes, did the AE recur or worsen?  
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or 
(2) the trial is a single- dose drug trial); or (3) Merck product(s) is/are used only one time).  
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS 
SERIOUS AND WHICH MAY HAVE BEEN CAUSED BY THE MER CK PRODUCT, OR IF 
REEXPOSURE TO THE MERCK PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE U.S. CLINICAL MONITOR AS PER DOSE MODIFICATION GUIDELINES IN THE 
PROTOCOL.  
 Consistency 
with Trial 
Treatment 
Profile  Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the 
Merck product or drug class pharmacology or toxicology?  
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician 
according to his/her best clinical judgment, including consideration of the above elements.  
Record one of the following  Use the following scale of criteria as guidance (not all criteria mus t be present to be indicative of 
a Merck product relationship).  
Yes, there is a reasonable 
possibility of Merck 
product relationship.  There is evidence of exposure to the Merck product.  The temporal sequence of the AE onset relative 
to the administration  of the Merck product is reasonable.  The AE is more likely explained by the 
Merck product than by another cause.  
No, there is not a reasonable 
possibility Merck product 
relationship Subject did not receive the Merck product OR temporal sequence of the AE  onset relative to 
administration of the Merck product is not reasonable OR there is another obvious cause of the AE.  
(Also entered for a subject with overdose without an associated AE.)  
 
9.2 Adverse Event Characteristics  
 
• CTCAE term (AE description) and grade:  The descriptions and grading 
scales found in the revised NCI Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0 will be utilized for AE reporting. All appropriate 
treatment areas should have access to a copy of the CTCAE version 4 .0. A 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 51 of 85 copy of the CTCAE version 4 .0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
 
• ‘Expectedness’ : AEs can be ‘Unexpected’ or ‘Expected’ (see Section 7.1 
above) for expedited reporting purposes only.   
 
• Attribution of the AE:  
 
- Definite – The AE is clearly  related to the study treatment.  
- Probable – The AE is likely  related to the study treatment.  
- Possi ble – The AE may be related to the study treatment.  
- Unlikely – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE is clearly NOT related to the study treatment.  
 
9.3 STRC SAE Reporting Requirements  
 
The Safety and Toxicity Reporting Committee (STRC) is responsible for reviewing SAEs 
for CCCWFU Institutional studies as outlined in Appendix B . STRC currently requires that 
all unexpected 4 and  all grade 5 SAEs on these trials be reported to them for review. All 
CCCWFU Clinical Research Management (CRM) s taff members assisting a P rincipal 
Investigator  in investigating, documenting and reporting an SAE qualifying for STRC 
reporting are responsible for informing a clinical member of the STRC as well as the entir e 
committee via the email notification procedure of the occurrence of an SAE.  
9.4  WFUHS IRB AE Reporting Requirements  
 
Any unanticipated problems involving risks to subjects or others and adverse events shall 
be promptly reported to the IRB , according to institutional policy . Reporting to the IRB is 
required regardless of the funding source, study sponsor, or whether the event involves 
an investigational or marketed drug, biologic or device. Reportable events are not limited 
to physical injury, but include psychological, economic and social harm.  Reportable events 
may arise as a result of drugs, biological agents, devices, procedures or other interventions, or as a result of questionnaires, surveys, observations or other interactions 
with research subjects . 
 
All members of the research team are responsible for the appropriate reporting to the IRB 
and other applicable parties of unanticipated problems involving risk to subjects or others. 
The Principal Investigator, however, is ultimately responsible for ens uring the prompt 
reporting of unanticipated problems involving risk to subjects or others to the IRB. The 
Principal Investigator is also responsible for ensuring that all reported unanticipated risks 
to subjects and others which they receive are reviewed t o determine whether the report 
represents a change in the risks and/or benefits to study participants, and whether any 
changes in the informed consent, protocol or other study -related documents are required.  
 
Any unanticipated problems involving risks to subjects or others occurring at a site where 
the study has been approved by the WFUHS IRB (internal events) must be reported to the 
WFUHS IRB within 7 calendar days of the investigator or other members of the study team 
becoming aware of the event.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 52 of 85  
Any unanticipated problems involving risks to subjects or others occurring at another site 
conducting the same study that has been approved by the WFUHS IRB (external events) 
must be reported to the WFUHS IRB within 7 calendar days of the investigator or other 
members of the study team becoming aware of the event.  
 
Any event, incident, experience, or outcome that alters the risk versus potential benefit of 
the research and as a result warrants a substantive change in the research protocol or 
informed consent proc ess/document in order to insure the safety, rights or welfare of 
research subjects.  
9.5 Merck  Reporting Requirements  
9.5.1  Reporting of Pregnancy and Lactation to the Sponsor and 
to Merck  
 
Although pregnancy and lactation are not considered adverse events , it is the 
responsibility of investigators or their designees to report any pregnancy or lactation in a subject (spontaneously reported to them), including the pregnancy of 
a male subject's female partner that occurs during the trial or within 120 days of  
completing the trial completing the trial, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.  All subjects 
and female partners of male subjects who become pregnant must be followed to the completion/termination of the pregnancy.  Pregnancy outcomes of 
spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, 
fetal death, intrauterine death, miscarriage and stillbirth must be reported as 
serious events (Important Medical Events).  If the pregnancy continues to term, the 
outcome (health of infant) must also be reported.  
 
Such events must be reported within 24 hours to the Sponsor and within 2 working 
days to Merck Global Safety. (Attn: Worldwide Product Safety; FAX 215 993-1220)  
 
9.5.2  Reporting of SAEs and Events of Clinical Interest  
   
Any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause other than progression of the cancer 
under study that occurs to any subject from the time the consent is signed 
through 90 days following cessation of treatment, or the initiation of new anti-cancer therapy, whichever is earlier, whether or not related to Merck 
product, must be reported within 24 hours to the Sponsor and within 2 working days to Merck Global Safety.  
 
Non-serious Events of Clinical Interest will be forwarded to Merck Global 
Safety and will be handled in the same manner as SAEs.  
 
Additionally, any serious adverse event, considered by an investigator who 
is a qualified physician to be related to Merck product that is brought to the 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 53 of 85 attention of the investigator at any time outside of the time period specified 
in the previous paragra ph also must be reported immediately to the 
Sponsor and to Merck.  
 
SAE reports and any other relevant safety information are to be 
forwarded to the Merck Global Safety facsimile number:  +1- 215-993-
1220 
 
A copy of all 15 Day Reports and Annual Progress Reports is submitted as 
required by FDA, European Union (EU), Pharmaceutical and Medical 
Devices agency (PMDA) or other local regulators. Investigators will cross 
reference this submission according to local regulations to the Merck 
Investigational Compound N umber (IND, CSA, etc.) at the time of 
submission.  Additionally investigators will submit a copy of these reports 
to Merck & Co., Inc. (Attn: Worldwide Product Safety; FAX 215 993- 1220) 
at the time of submission to FDA.  
 
All subjects with serious adverse events must be followed up for outcome.  
10.0 Pharmaceutical Information  
 A list of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 9.0. 
 
10.1 Pharmaceutical A ccountability  
 
Drug accountability logs will be maintained for all investigative agents used under 
this protocol. These logs shall record quantities of study drug received and quantities dispensed to patients, including lot number, date dispensed, patient 
identifier number, patient initials, protocol number, dose, quantity returned, 
balance remaining, and the initials of the person dispensing the medication.  
10.2 Pembrolizumab  
 
  Clinical Supplies will be provided by Merck as summarized below . 
 
Product Name & Potency  Dosage Form  
Pembrolizumab 50 mg  Lyophilized Powder for Injection  
Pembrolizumab 100 mg/ 4mL  Solution for Injection  
 
Packaging and Labeling Information  
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
 
 
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 54 of 85 Clinical Supplies Disclosure 
This trial is open- label; therefore, the subject, the trial site personnel, the Sponsor 
and/or designee are not blinded to treatment. Drug identity (name, strength) is 
included in the label text; random code/disclosure envelopes or lists are not 
provided.  
 
Marketed Packs:  When Study Drug is provided in the marketed package, Merck 
will not supply any Chemistry, Manufacturing, Control (CMC) information. 
Institution’s regulatory submission should reference t he Merck Marketing 
Authorization. If any additional labelling of containers is required, e.g. to add Study Protocol number, and it has not been agreed for Merck to perform the 
additional labelling, it is Institution’s responsibility to arrange for this act ion to be 
done in accordance with U.S. regulations.  
 
Storage and Handling Requirements  
The lyophilized drug product after reconstitution with sterile water for injection, and 
the liquid drug product are a clear to opalescent solutions, essentially free of visible 
particles.  The reconstituted lyophilized product and the liquid product are intended 
for IV  administration. The reconstituted drug product solution or the liquid drug 
product can be  further diluted with normal saline or 5% dextrose in the 
concentra tion range of  1 to 10 mg/mL in intravenous (IV) containers made of 
polyvinyl chloride (PVC) or non -PVC material. Reconstituted vials should be 
immediately used to prepare the infusion solution in the IV bag and the infusion 
solution should be immediately administered. Diluted pembrolizumab solutions 
may be stored at room temperature for a cumulative time of up to  4 hours. This 
includes room temperature storage of admixture solutions in the IV bags and the 
duration of infusion. In addition, IV bags can be s tored at 2 to 8° C for up to a 
cumulative time of 20 hours. This recommendation is based on up to 24 hours of 
room temperature and  up to 24 hours of refrigerated stability data of diluted MK -
3475 solutions in the IV bags.  
 
Clinical supplies must be stored i n a secure, limited- access location.  The drug 
product is  to be  stored as  a stable lyophilized powder or liquid solution under 
refrigerated conditions (2 to 8° C). 
 
Receipt and dispensing of trial medication must be recorded by an authorized 
person at the tr ial site.  Clinical supplies may not be used for any purpose other 
than that stated in the protocol.  
 
Returns and Reconciliation  
 
The investigator is responsible for keeping accurate records of the clinical supplies 
received from Merck or designee, the amount dispensed to and returned by the 
subjects and the amount remaining at the conclusion of the trial.  
Upon completion or termination of the study, all unused and/or partially used 
investigational product will be destroyed at the site per institutional pol icy. It is the 
Investigator’s responsibility to arrange for disposal of all empty containers, 
provided that procedures for proper disposal have been established according to 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 55 of 85 applicable federal, state, local and institutional guidelines and procedures, and 
provided that appropriate records of disposal are kept.  
10.3 Paclitaxe l  
  
Product description :  Supplied as:  
 
NDC 0015 -3475 -30 30 mg/5 mL multidose vial individually packaged in a 
carton  
NDC 0015 -3476 -30 100 mg/16.7 mL multidose  vial individually packaged in a 
carton  
NDC 0015 -3479 -11 300 mg/50 mL multidose vial individually packaged in a 
carton  
 Solution preparation :  Paclitaxel Injection must be diluted prior to infusion. 
Paclitaxel should be diluted in 0.9% Sodium Chloride In jection, USP; 5% Dextrose 
Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% 
Dextrose in Ringer’s Injection to a final concentration of 0.3 to 1.2 mg/mL. 
Parenteral drug products should be inspected visually for particulate matter and 
discoloration prior to administration whenever solution and container permit. Upon 
preparation, solutions may show haziness, which is attributed to the formulation 
vehicle. Paclitaxel solutions should be prepared and stored in glass, 
polypropylene, or polyolefin containers. Non- PVC containing administration sets, 
such as those which are polyethylene- lined, should be used.  
 
Storage requirements:   Store the vials in original cartons between 20° –25° C 
(68°–77° F). Retain in the original package to protect f rom light.  
 
Stability:   Unopened vials of paclitaxel  injection are stable until the date indicated 
on the package when stored between 20° –25° C (68° –77° F), in the original 
package. Neither freezing nor refrigeration adversely affects the stability of the 
product. Upon refrigeration, components in the paclitax el vial may precipitate, but 
will redissolve upon reaching room temperature with little or no agitation. There is no impact on product quality under these circumstances. If the solution remains 
cloudy or if an insoluble precipitate is noted, the vial shoul d be discarded. Prepared 
solutions are physically and chemically stable for up to 27 hours at ambient 
temperature (approximately 25° C) and room lighting conditions.  
 
Route of administration:   Paclitaxel should be administered as an intravenous 
infusion th rough an in- line filter with a microporous membrane not greater than 
0.22 microns. Monitor infusion site for possible infiltration during drug 
administration.  
 
Disposal:   To minimize the risk of dermal exposure, always wear impervious 
gloves when handling vials containing paclitaxel Injection. If paclitaxel solution 
contacts the skin, wash the skin immediately and thoroughly with soap and water. 
Following topical exposure, events have included tingling, burning, and redness. If 
paclitaxel contacts mucous m embranes, the membranes should be flushed 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 56 of 85 thoroughly with water. Upon inhalation, dyspnea, chest pain, burning eyes, sore 
throat, and nausea have been reported.  
11.0 Correlative/Special Studies  
 
11.1 Laboratory Correlative Studies  
  
Peripheral blood will be obtained from each patient prior to initiation of treatment,  
on cycle 4 day 1, cycle 8  day 1, and  at the end -of-treatment visit.    A total of six 
(6)  
10mL EDTA tubes will be drawn at each time point.   
 
Changes from baseline and in responding versus nonresponding patients will be 
assessed.   
 
(1) Activated T -cells:  The goal is to calculate the number and percentage of 
IFNγ+CD8+ T cells in peripheral blood pre-, on-, and post -treatment . 
i. Sample collection.   Peripheral blood will be obtained from each patient prior 
to initiation of treatment, on cycle 4 day 1, cycle 8 day 1, and at the end- of-
treatment visit.  The lymphocyte fraction will be isolated on a Percoll 
gradient.   
ii. T-cell processing.   Cells will be  stimulated overnight with plate- bound anti -
CD3 (1ug/mL) and soluble anti -CD28 (1ug/mL) in the presence of protein 
transport inhibitors Brefeldin A and monensin.  Following stimulation, cells 
will be stained with anti -CD8-FITC antibody, fixed and permeabil ized using 
the BD Cytofix/Cytoperm staining kit.   Following permeabilization the cells 
will be stained with anti -IFNg, anti -IL-12, anti -IL2. Stained cells will be run 
on a FACS Canto and analyzed using manufacturer provided software. The 
proportion of IFN g+CD8+ T cells will be quantified, with expression of IL -
12 considered further evidence of activated effector function.  
 
(2) MDSC and Tregs:    The goal is to determine whether combination treatment 
changes the number and proportion of MDSC and Tregs in peripher al blood.  
i. Sample collection.   Peripheral blood will be obtained from each patient prior 
to initiation of treatment, on cycle 4 day 1, cycle 8 day 1, and at the end- of-
treatment visit.  The lymphocyte fraction will be isolated on a Percoll 
gradient.   
ii. MDSC and T- reg processing.  Tregs will be quantified using the human 
Treg staining kit (eBioscience) and established methods.  
 
(3) MicroRNAs :  The goal is to explore changes in circulating and urinary immune -
regulatory microRNAs during treatment, using quantitative real time PCR.  
i. Sample collection.  Blood and urine will be collected each patient prior to 
initiation of treatment, on cycle 4 day 1, cycle 8 day 1, and at the end- of-
treatment visit.  10 mL of blood will be drawn into EDTA  tubes.  Peripheral 
blood mononuc lear cells (P BMC) and plasma will be separated by gradient 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 57 of 85 centrifugation.  Urine is  centrifuged at 1000 g  for 10 minutes to pellet 
cellular debris. All samples are aliquoted and stored at −80°C until further 
use.  
ii. miRs  processing.  Total RNA will be isolated from plasma and urine using 
the miRNeasy Mini Kit (Qiagen) collected pre -, on-, and post-therapy.     
Pools of plasma samples collected from healthy donors will be tested as 
controls.  Plasma levels  of selected miRs will be measur ed with qRT -PCR, 
normalized to spiked- in synthetic miR, in all patients pre - and post -therapy .  
Reverse transcription reactions are performed using a TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions. qRT -PCR will be performed using the reverse 
transcription reaction product, TaqMan MicroRNA Assay kits, and TaqMan 
Universal PCR Master Mix (Applied Biosystems. The ΔΔC T method is used 
to determine relative levels (RQ).  Data are normalized to a C. eleg ans 
synthetic miR sequence, cel -miR- 39 (Qiagen), which is spiked in as a 
control during RNA isolation.  
 
11.2 Pathology Correlative Studies  
 
When feasible, a metastatic biopsy will be performed.  Archived tumor TURBT and  
cystectomy  specimens will also be accessed.  The goal will be to determine PD -L1  
expression and to analyze cytotoxic T- cell number and function, MDSC, and Treg cells  
in tumor tissue.  
 
(1) Tumor PD -L1 expression:  Biopsy samples will be stored and batched for PD -L1 
immunohistochemistry.  This will be done with QualTek per Merck’s guidelines.  Five 
(5) unstained slides per patient, cut from a formalin- fixed, paraffin- embedded (FFPE) 
tissue block, will be sent to Q ualTek for PD -L1 staining.   Positively charged ProbeOn 
Plus slides must be used for tissue sections.  Samples may be held as blocks 
indefinitely at the site and then cut in batches. Slides must be shipped to QualTek 
immediately after sectioning to comply with the protocol’s testing requirements.  
Sectioned slides must be shipped cold (2- 8°C) and in the dark using the shipping 
materials provided by QualTek.  Sectioned slides provided should contain tumor 
specimen sufficient for pathology review and analysis  of tumor sample. If available, 
greater than 50% tumor content is preferred.  Fine- needle aspiration, brushing, cell 
pellet from pleural effusion, bone metastases, lavage specimen, frozen sample,  plastic  
embedded sample,  or formalin  fixed  sample that was frozen at any point  will not be 
accepted for IHC analysis. Needle core biopsies that are formalin- fixed and paraffin-
embedded are acceptable.  The slides will be evaluated by a Qualtek -associated 
pathologist for review of biomarker staining expression levels.  
 
(2) Tumor immune cells:  Cytotoxic T -cell number and function, MDSC, and Treg cells 
in tumor tissue will be evaluated in both archival tissue and in fresh biopsy specimens. Tumor tissue will be digested with DNase and Collagenase using standard protoc ols, 
and CD8+ T cells will be isolated by flow sorting. Sorted T cells will be stimulated with 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 58 of 85 anti-CD3/anti -CD28, and expression of IFNg and IL- 12 will be quantified by flow 
cytometry to determine proportion of functional T -cells.  For detection of Tregs in 
biopsy samples, CD4+CD25+ T cells will be isolated by flow sorting, and post -stained 
for FoxP3.  To detect MDSC, Gr+ and CD11b+ cells will be sorted and confirmed by 
Wright -Giemsa staining of sorted cells.  Concordance of immune cell frequency 
between archival and fresh specimens and the peripheral blood from the same patient will be informative.
  
12.0 Data Management  
 
 
Informed consent document  ORIS  
Protocol registration form  ORIS  
Adverse Events  ORIS  
Baseline Data Collection Form  REDCap  
Follow -Up Data Collection Form  REDCap  
Treatment Evaluation Response Form  REDCap  
13.0 Statistical Considerations  
 
13.1 Power, Sample Size  and Accrual Rate  
 
Simon's minimax two- stage design37 will be used. The null hypothesis that the true 
response rate is 24% will be t ested against a one- sided alternative. In the first 
stage, 15 patients will be accrued. If there are 3 or fewer responses in these 15 
patients, the study will be stopped. Otherwise, 12 additional patients will be 
accrued for a total of 27. The null hypothesis will be rejected if 10 or more 
responses are observed in 27 patients. This design yields a type I error rate of .09 
and power of 90% when the true response rate is 48%.    We anticipate an accrual 
rate of 1 -2 patient s per month or 12- 24 patients per year.   
13.2 Analysis of Primary Objective  
 
The primary endpoint will be overall response rate.  The analysis will be 
performed in all patients that are evaluable for efficacy and will have one interim 
analysis.  In this phase 2 trial, we will calculate the overall response rate (primary 
outcome) and 6- month PFS.   For the overall response rate, if 10 or more 
responses are observed in the 27 patients, we will reject the null hypothesis that 
the response rate is 24% or less.   
13.3 Analysis of Secondary Objecti ves 
 
The secondary endpoints include PFS and safety. We will estimate PFS at 6-
months using the Kaplan -Meier method on all evaluable patients. All AEs will be 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 59 of 85 tabulated and presented by preferred term and/or system organ class and grade.  
All deaths and SA Es will be tabulated. The 6- month PFS will be compared to 
historical rates using a chi -square test.  
 13.4 Analysis of Correlative Objectives  
 
The correlative endpoints include immune effects.  They will be analyzed in 
exploratory analyses to associate their levels with tumor response. Categorical 
endpoints will be analyzed using chi -square or Fisher’s exact tests, and continuous 
measures will be compared using t -tests to compare response groups.  
References  
 
1. Cancer Facts & Figures 20 15. Atlanta: American Cancer Society.  
2. von der Maase H, Sengelov L, Roberts JT, et al. Long -term survival results of a randomized trial 
comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in 
patients with bladder cancer. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology. Jul 20 2005;23(21):4602- 4608.  
3. Blank C, Brown I, Peterson AC, et al. PD -L1/B7H -1 inhibits the effector phase of tumor rejection 
by T cell receptor (TCR) transgenic CD8+ T cells. Cancer research. Feb 1 2004;64(3):1140- 1145.  
4. Chen DS, Irving BA, Hodi FS. Molecular pathways: next -generation immunotherapy --inhibiting 
programmed death- ligand 1 and programmed death- 1. Clinical cancer research : an offici al 
journal of the American Association for Cancer Research. Dec 15 2012;18(24):6580- 6587.  
5. Plimack E, Gupta S, Bellmunt J, et al. A phase 1b study of pembrolizumab in patients with advanced urothelial tract cancer. ESMO annual meeting. 2014;LBA23.  
6. Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor -infiltrating myeloid cell subsets 
in patients with bladder cancer. International journal of cancer. Journal international du cancer. 
Mar 1 2012;130(5):1109- 1119.  
7. Brandau S, Trellakis S, Bruderek K, et al. Myeloid- derived suppressor cells in the peripheral 
blood of cancer patients contain a subset of immature neutrophils with impaired migratory 
properties. Journal of leukocyte biology. Feb 2011;89(2):311- 317. 
8. Loskog A, Ninalga C, Paul -Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH. Human 
bladder carcinoma is dominated by T -regulatory cells and Th1 inhibitory cytokines. The Journal of 
urology. Jan 2007;177(1):353- 358. 
9. Horn T, Grab J, Schusdziarra J, et al. Antitumor T cell responses in bladder cancer are directed 
against a limited set of antigens and are modulated by regulatory T cells and routine treatment 
approaches. International journal of cancer. Journal international du cancer. Nov 
2013;133(9):2145- 2156.  
10. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K. 
Immunosuppressive activity of CD14+ HLA -DR- cells in squamous cell carcinoma of the head 
and neck. Cancer science. Jun 2012;103(6):976- 983. 
11. Kim K, Skora AD, Li Z, et  al. Eradication of metastatic mouse cancers resistant to immune 
checkpoint blockade by suppression of myeloid- derived cells. Proceedings of the National 
Academy of Sciences of the United States of America. Aug 12 2014;111(32):11774- 11779.  
12. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor 
eradication by combining CTLA -4 or PD -1 blockade with CpG therapy. Journal of immunotherapy. 
Apr 2010;33(3):225- 235. 
13. Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short -term versus prolonged 
treatment [German Association of Urological Oncology (AUO) trial AB 2 0/99]. Annals of oncology 
: official journal of the European Society for Medical Oncology / ESMO. Feb 2011;22(2):288- 294. 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 60 of 85 14. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel 
in patients with previously treated advanced urothelial cancer. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. Feb 15 2002;20(4):937- 940. 
15. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional -cell carcinoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. May 1997;15(5):1853- 1857.  
16. Yuan L, Wu L, Chen J, Wu Q, Hu S. Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine. Jun 17 2010;28(27):4402- 4410.  
17. Huang X, Huang G, Song H, Chen L. Preconditioning chemotherapy with paclitaxel and cisplatin 
enhances the antitumor activity of cytokine induced- killer cells in a murine lung carcinoma model. 
International journal of cancer. Journal international du cancer. Aug 1 2011;129(3):648- 658. 
18. Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of 
myeloid -derived suppressor cells and chronic inflammation in the spontaneous melanoma model. 
Journal of immunology. Mar 1 2013;190(5):2464- 2471.  
19. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD -1 blockade and GITR triggering 
induce a potent antitumor immunity in murine cancer models and synergizes with 
chemotherapeutic drugs. Journal of translational medicine. 2014;12:36.  
20. Wei H, Zhao L, Li W, et al. Combinatorial PD -1 blockade and CD137 activation has therapeutic 
efficacy in murine cancer models and synergizes with cisplatin.  PloS one. 2013;8(12):e84927.  
21. Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer -induced immunosuppressive 
cells. Cancer research. May 15 2014;74(10):2663- 2668.  
22. Daud AI, Hamid O, Ribas A, et al. Antitumor activity of the anti -PD-1 monocl onal antibody MK -
3475 in melanoma: Correlation of tumor PD -L1 expression with outcome.  AACR Annual Meeting. 
2014;Abstract CT104.  
23. Gandhi L, Balmanoukian A, Hui R, et al. MK -3475 (anti -PD-1 monoclonal antibody) for non- small 
cell lung cancer (NSCLC): Ant itumor activity and association with tumor PD -L1 expression. AACR 
Annual Meeting. 2014; Abstract CT105.  
24. Bellmunt J, Mullane SA, Werner L, et al. Association of PD -L1 expression on tumor -infiltrating 
mononuclear cells and overall survival in patients with urothelial carcinoma. Annals of oncology : 
official journal of the European Society for Medical Oncology / ESMO. Jan 18 2015.  
25. Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high- risk metastatic melanoma. 
Clinical cancer research : an official jour nal of the American Association for Cancer Research. 
Feb 15 2015;21(4):712- 720. 
26. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab- refractory or - naive melanoma. Journal of clinical oncology :  official journal 
of the American Society of Clinical Oncology. Dec 1 2013;31(34):4311- 4318.  
27. Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high 
sensitivity for bladder cancer. British journal of cancer. Jun 26 2012;1 07(1):123- 128. 
28. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor 
marker: microRNA -126 and microRNA -182 are related to urinary bladder cancer. Urologic 
oncology. Nov-Dec 2010;28(6):655- 661. 
29. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. 
Urologic oncology. Nov 2013;31(8):1701- 1708.  
30. Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and 
microRNA in patients with uveal melanoma deve loping metastatic disease. Molecular 
immunology. Apr 2014;58(2):182- 186. 
31. Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony 
stimulating factor. Journal of immunotherapy. Sep 2012;35(7):587- 594. 
32. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role 
in patients with renal insufficiency and as salvage therapy. The Journal of urol ogy. Nov 
1996;156(5):1606- 1608.  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 61 of 85 33. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in 
pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. British 
journal of cancer. 1997;75(4):606- 607. 
34. Seidman AD, Hudis CA, Albanell J, et al. Dose- dense therapy with weekly 1- hour paclitaxel 
infusions in the treatment of metastatic breast cancer. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology. Oct 1998;16(10):3353- 3361.  
35. Friedland DM, Dakhil S, Hollen C, Gregurich MA, Asmar L. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer investigation. 2004;22(3):374-
382. 
36. Eisenhauer EA, Therasse P, Bogaerts  J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 
Jan 2009;45(2):228- 247. 
37. Simon R. Optimal two- stage designs for phase II clinical trials. Controll ed clinical trials. Mar 
1989;10(1):1- 10. 
 
 
 
 
 
 
 
 
 
  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 62 of 85 Appendix A – Protocol Registration Form  
 
DEMOGRAPHICS  
Patient: Last Name: _____________________  First Name: ___________________________  
MRN:          ___ ___ ___ ___ ___ ___ ___ ___  DOB (mm/dd/yy): ___ ___ / ___ ___ / ___ ___  
ZIPCODE:  ___ ___ ___ ___ ___    
SEX:     Male      Female  Ethnicity (choose one):    Hispanic  
Non -Hispanic  
Race (choose all that apply):   WHITE           BLACK            ASIAN  
 PACIFIC ISLANDER                 NATIVE AMERICAN 
 
Height:   ___ ___.___ inches  Weight: ___ ___ ___.___lbs.(actual)  
Surface Area: ___ ___.___m2    
Primary Diagnosis: ____________________________________________________________  
Date of Diagnosis: ___ ___ /___ ___/___ ___   
ECOG Performance Status: ___  
 
 
Protocol Registrar can be contact by calling 336- 713-6767 between 8:30 AM and 4:00 PM, Monday –  Friday.  
 
Completed Eligibility Checklist and Protocol Registration Form must be hand delivered, faxed or e- mailed to 
the registrar at 336- 7136772 or registra@wakehealth.edu . 
 PROTOCOL INFORMATION  
Date of Registration:  ___ ___ / ___ ___ / ___ ___  
MD Name (last) :  ______________________       
Date protocol treatment started:  ___ ___ / ___ ___ / ___ ___  
Informed written consent:  
(consent must be signed prior to 
registration)   YES   NO 
 
Date Consent Signed:  ___ ___ / ___ ___ / ___ ___  
 
PID # (to be assigned by ORIS):  ___ ___ ___ ___ ___ ___ ___ ___  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 63 of 85 Appendix B – Subject Eligibility Checklist  
 
 
IRB Protocol No.   CCCWFU Protocol No.  
Study Title: Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Princip al Investigator: Rhonda Bitting, MD  
 
Inclusion Criteria  
(as outlined in study protocol)  Criteria 
is met  Criteria is 
NOT met  Source Used to  Confirm *  
(Please document dates and lab results)  
Patients diagnosed with platinum -refractory 
metastatic urothelial cancer that is measureable based on Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria 1.1.  Platinum -refractory 
disease is defined as progressive disease on 
cisplatin or carboplatin therapy or within 12 
months of prior platinum treatment  (last dose .) □ □  
At least 1 prior chemotherapy regimen containing 
cisplatin or carboplatin.  □ □  
Be willing to provide tissue from a newly obtained 
core or excisional biopsy of a tumor lesion.  
Newly -obtained is defined as a specimen 
obtained up to 6 months  (168 days) prior to 
initiation of treatment on Day 1.  Archived 
specimen can be used for subject s, if available.  □ □  
Age >18 years.  □ □  
Performance status of 0 or 1 on the ECOG 
Performance  Scale.  □ □  
Adequate organ function as defined below : 
ANC ≥ 1,500/mcL  
Platelets ≥ 80,000/mcL  
Hemoglobin ≥9 g/dL without transfusion dependency.  
Serum Creatinine  OR   
    Measured or Calculated Creatinine Clearance  
    (GFR can also be used in place of creatinine or CrCl)  
      ≤1.5x  upper limit of normal (ULN) OR  
      ≥ 35 mL/min for s ubject with creatinine levels > 1.5x 
institutional ULN  
Serum Total bilirubin ≤ 1.5 x ULN OR 
     Direct bilirubin ≤ ULN fo r subjects with t otal bilirubin 
levels > 1.5x  ULN 
AST (SGOT) and ALT (SGPT) ≤ 2.5x  ULN  OR ≤ 5x 
ULN for subjects with liver metastases  
Albumin >2.5 mg/dL  
 □ □  
Female subjects of childbearing potential should 
have a negative urine or serum pregnancy within 
72 hours prior to receiving the first dose of study 
medication. If the urine test is positive or cannot 
be confirmed as negative, a serum pregnancy test 
will be required.  □ □  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 64 of 85 Inclusion Criteria  
(as outlined in study protocol)  Criteria 
is met  Criteria is 
NOT met  Source Used to  Confirm *  
(Please document dates and lab results)  
Female subjects of childbearing potential should 
be willing to use 2 methods of birth control or be 
surgically sterile, or abstain from heterosexual 
activity for the course of the study through 120 
days after the last dose of study medication. 
Subjects of childbearing potential are those who 
have not been surgically sterilized or have not 
been free  from menses for >1 year.  □ □  
Male subjects should agree to use an adequate 
method of contraception starting with the first dose of study therapy through 120 days after the 
last dose of study therapy.  □ □  
Ability to understand and the willingness to si gn 
an IRB -approved informed consent document.  □ □  
Exclusion Criteria  
(as outlined in study protocol) Criteria 
NOT 
present  Criteria is 
present  Source Used to  Confirm *  
(Please document dates and lab results)  
Currently receiving or has had treatment with an 
investigational agent or used an investigational 
device within 4 weeks of study Day 1.  □ □  
Anti-cancer monoclonal antibody (mAb) within 4 
weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from 
adverse events due to agents administered more 
than 4 weeks earlier.  □ □  
Chemotherapy, targeted small molecule therapy, 
or radiation therapy within 2 weeks prior to study 
Day 1 or who has not recovered (i.e., ≤ Grade 1 
or at baseline) from adverse events due to a 
previously administered agent.  
 
Note:  Subjects with ≤ Grade 2 neuropathy are an 
exception to this criterion and may qualify for the 
study.  
 
Note:  If subject received major surgery, they must have recovered adequately from the toxicity 
and/or complications from the intervention prior to 
starting therapy.  □ □  
Prior therapy with an anti -PD-1, anti -PD-L1, or 
anti-PD-L2 agent.  Prior therapy with paclitaxel or 
docitaxel.  □ □  
Hypersensitivity to pembrolizumab, any of its 
excipients, paclitaxel, or any of its excipients.  □ □  
Diagnosis of immunodeficiency or is receiving 
systemic steroid therapy or any other form of 
immunosuppressive therapy within 7 days prior to 
the first dose of trial treatment.  □ □  
Known history of active TB   (Bacillus 
Tuberculosis) . □ □  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 65 of 85 Inclusion Criteria  
(as outlined in study protocol)  Criteria 
is met  Criteria is 
NOT met  Source Used to  Confirm *  
(Please document dates and lab results)  
Known additional malignancy that is progressing 
or requires active treatment.  Exceptions include 
basal cell carcinoma of the skin or squamous cell 
carcinoma of the skin that has undergone 
potentially curative therapy or in situ cervical 
cancer.  □ □  
Known active central nervous system (CNS) 
metastases and/or carcinomatous meningitis.  
Subjects with previously treated brain metastases 
may participate provided they are stable (without 
evidence of progression by imaging for at least 
four weeks prior to t he first dose of trial treatment 
and any neurologic symptoms have returned to 
baseline), have no evidence of new or enlarging 
brain metastases, and are not using steroids for at 
least 7 days prior to trial treatment.  This 
exception does not include carcinomatous 
meningitis which is excluded regardless of clinical 
stability.  □ □  
Active autoimmune disease that has required 
systemic treatment in the past 2 years (i.e. with 
use of disease modifying agents, corticosteroids 
or immunosuppressive drugs). Replacement 
therapy (eg., thyroxine, insulin, or physiologic 
corticosteroid replacement therapy for adrenal or 
pituitary insufficiency, etc.) is not considered a 
form of systemic treatment.  □ □  
Known history of, or any evidence of active, non -
infectious pneumonitis.  □ □  
Active infection requiring systemic therapy.  □ □  
History or current evidence of any condition, 
therapy, or laboratory abnormality that might confound the results of the trial, interfere with the 
subject’s participation for the full dur ation of the 
trial, or is not in the best interest of the subject to participate, in the opinion of the treating 
investigator.   □ □  
Known psychiatric or substance abuse disorders 
that would interfere with cooperation with the 
requirements of the trial.  □ □  
Pregnancy or breastfeeding, or expecting to 
conceive or father children within the projected duration of the trial, starting with the pre- screening 
or screening visit through 120 days after the last 
dose of trial treatment.  □ □  
Known history of Hum an Immunodeficiency Virus 
(HIV) (HIV 1/2 antibodies).  □ □  
Known active Hepatitis B (e.g., HBsAg reactive) 
or Hepatitis C (e.g., HCV RNA [qualitative] is 
detected).  □ □  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 66 of 85 Inclusion Criteria  
(as outlined in study protocol)  Criteria 
is met  Criteria is 
NOT met  Source Used to  Confirm *  
(Please document dates and lab results)  
Received a live vaccine within 30 days of planned 
start of study therapy.  
Note:  Seasonal influenza vaccines for injection 
are generally inactivated flu vaccines and are 
allowed; however intranasal influenza vaccines 
(e.g., Flu -Mist®) are live attenuated vaccines, and 
are not allowed.  □ □  
 
This subject is       eligible  /  ineligible     for participation in this study.  
 
ORIS Assigned PID: __________________         
 
Signature of  research professional confirming eligibility:_______________________ Date: _______________ 
 
Signature of Treating Physician**:  _____________________________________ Date:  _______________ 
 
* Examples of source documents include clinic note, pathology report, laboratory results, etc. When listing the source, 
specifically state which document in the medical record was used to assess eligibility. A lso include the date on the 
document. Example: “Pathology report, 01/01/14” or “Clinic note, 01/01/14”  
 
**Principal Investigator signature can be obtained following registration if needed
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -refractory 
urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 67 of 85 Appendix C – Race & Ethnicity Verification Form  
 
Thank you so much for helping us to verify your race and ethnicity to ensure the quality of our informatio n. As 
a brief reminder, the information you provide today will be kept confidential.  
 
1. Are you:  
Hispanic or Latino/a  
Not Hispanic or Latino/a  
 
2. What is your race? One or more categories may be selected.  
White or Caucasian  
Black or African American  
American Indian or Alaskan Native  
Asian  
Native Hawaiian or Other Pacific Islander  
Other, Please Specify: ___________________________  
          
  
 
Internal use only:  
  
 Name: ____________________ MRN#: ____________________  
 
Was the self -reported race and ethnicity of the participant verified at the time of consent?  
Yes        No  
 
Was a discrepancy found?       Yes         No  
         If yes, please provide what is currently indicated in the EMR:  
  Ethnicity:  ____________________   Race:  ____________________  
Additional comments: __________________________________________________________________  
_____________________________________________________________________________________  
_____________________________________________________________________________________  
 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 68 of 85 Appendix D – Mandatory STRC SAE Reporting Guidelines  
 
Safety and Toxicity Review Committee 
(STRC)  Serious Adverse Event (SAE) 
Notification SOP       Date: 07/10/2019  
 
 
Mandatory STRC SAE Reporting Requirements in WISER   
This document describes reporting requirements of adverse events from  WFBCCC  Investigator 
Initiated interventional trials to the Safety and Toxicity Review Committee (STRC).  A trial  is 
considered a  WFBCCC Investigator Initiated inter ventional trial  if the following criteria are met:   
  
1. The Principal Investigator (PI) of the trial is a member of a department at 
the Wake Forest University Baptist Medical  Center.   
2. WFBCCC is considered as the primary contributor to the design, 
implementat ion and/or  monitoring of the  trial.   
3. The trial is designated as “Interventional” using the Clinical Research  Categories 
definitions provided by the NCI in the Data Table 
4 documentation.  (https://cancercenters.cancer.gov/GrantsFunding/DataGuide#dt4 )  
  
There are two distinct types of WFBCCC Investigator Initiated interventional trials based  on where 
patient enrollment occurs.   These  include:   
  
1. Local WFBCCC Investigator Initiated interventional trials defined as trials 
where  all patients are enrolled fro m one of the WFBCCC sites.  These include the 
main  outpatient  Cancer Center clinics (located in Winston -Salem) as well as WFBCCC 
affiliate  sites located in Bermuda Run (Davie Medical Center), Clemmons, Lexington, High 
Point,  or Wilkesboro.   
2. Multi -Center WFB CCC Investigator Initiated interventional trials defined as 
trials  where  patients are enrolled from other sites in addition to WFBCCC sites.     
There are three types of trials that are included in this  category:   
a. Trials sponsored by the NCI Community Oncology Research Program  (NCORP) 
that are conducted at multiple sites where the PI is a member of a department  at the 
Wake Forest University Baptist Medical  Center.   
b. Trials sponsored by Industry that are conducted at multiple sites and the PI is  a 
member of a department at the Wake Forest University Baptist Medical  Center.   
c. Trials sponsored by WFBCCC that are conducted at multiple sites and the PI is  a 
member of a department at the Wake Forest University Baptist Medical  Center.   
  
All Adverse Events (AEs)  and Serious Adverse Events (SAEs) that occur on any patients  enrolled on 
WFBCCC Investigator Initiated Interventional trials must be entered into the WISER  system. The 
only  exception to this requirement is  for patients enrolled on NCORP trials at  non- WFBC CC sites. 
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 69 of 85 AEs and SAEs for NCORP patients enrolled at WFBCCC sites must be entered  into the WISER 
system. Once these AEs and SAEs are entered in WISER, certain actions must  be taken regarding 
the reporting of specific Adverse Events to the  STRC.   
All Adver se Events that occur during protocol intervention (defined below) and are coded  as either 
1) unexpected grade 4,  2) unplanned inpatient  hospitalization > 24 hours  (regardless of 
grade) , or grade 5 (death)  must be reported to the STRC using the using the SA E console in  WISER.   
  
A research nurse or clinical research coordinator when made aware that an adverse  event  meets one 
of the above criteria has occurred on a WFBCCC Investigator Initiated  interventional trial, is 
responsible for informing a clinical mem ber of the STRC by phone (or in -person)  about  the adverse 
event.  The nurse/coordinator should contact the treating physician prior to calling the STRC clinical 
member to obtain all details of the SAE, as well as all associated toxicities to be  recorded alo ng with 
the SAE.  In addition, this nurse or coordinator is responsible for entering the  adverse  event 
information into the SAE console in WISER.   Once the adverse event has been  entered into  the SAE 
console an email informing the entire STRC committee will be generated.   
  
THESE REPORTING REQUIREMENTS APPLY TO any staff member on the study team for  a WFBCCC 
Institutional Interventional trial. Ultimately, the protocol PI has 
the primary  responsibility  for AE identification,  documentation,  grading  and assignm ent of attribution
 to the investigational agent/intervention. However, when an AE event as described 
above  is observed, it is the responsibility of the person who observed the event to be sure that 
it is reported to the  STRC.   
  
What is considered during protocol  intervention?   
During protocol intervention  is considered to be  the time period while a patient is on  study  treatment 
or during the time period within 30 days of last study treatment (even if patient  begins a new (non -
study) treatment during the 3 0 days). This window of 30 days should be  the standard window to be 
used in all protocols unless a specific scientific rationale is presented  to suggest that a shorter 
window can be used to identify  events.  If it is a trial sponsored by Industry and the sp onsor requires a 
longer window for monitoring of SAEs, then the longer window of time specified by the sponsor 
should be  followed.   
  
What is considered as an Unexpected Grade 4  event?   
Any grade 4 event that was not specifically listed as an expected adverse event in the protocol should 
be considered as unexpected. A grade 4 adverse event can  be considered to  be unexpected if it is an 
event that would not be expected based on the treatment being  received  or if it is unexpected based 
on the health of th e patient. In either case, if there is  any uncertainty about whether a grade 4 
adverse event is expected or unexpected it should  be reported to  STRC.   
  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 70 of 85 STRC notification responsibilities of the person (e.g., nurse) handling  the reporting/documenting of 
the SAE in  WISER:   
1. Make a phone call (or speak in person) to the appropriate clinical member of the  STRC as listed 
below (page if necessary)   
2. Enter  a new SAE  into the SAE  module that  is located  in the Subject>> CRA  Console  in WISER 
WITHIN 24 HOURS of first k nowledge of the event. Information can be  entered and  saved, 
but the STRC  members will not be notified  until a  date  is entered  into the STRC Notification Date 
Field. This will ensure that all persons that need to be made  aware of the event (i.e., study tea m 
members and STRC members) will be  notified;  remember to file a copy of the  confirmation.   
3. Document that the appropriate person(s) on the STRC has been contacted. Indicate the name of 
the STRC clinician that was contacted in the Event Narrative  field  in the SAE  console of 
the particular subject.   
4. Document  whether or not the protocol should be suspended based on the  discussion  with the 
STRC clinician. This is the major function of the email notification. Enter whether the protocol 
should be suspended in the  Event Narrative  Field.   
5. Follow up/update the clinical member(s) of STRC regarding any new developments 
or information obtained  during the course of  the SAE investigation and reporting process.   
  
Elements  needed  to complete  the SAE form  in the Subject  Console in WISER  (see  Screen Shot  3):  
1. Event  Date   
2. Reported  Date   
3. Reported  by  
4. If Grade 5, enter Death  Date   
5. If Grade 5, enter Death occurred: within 30  days   
6. Event Narrative: Brief description (include brief clinical history relevant to this  event,  including 
therapies believed related to event). Begin narrative with the STRC  clinician who was  notified  and 
Date/Time notified. In addition, state attribution by STRC  clinician as either “Unrelated”, “Unlikely”, 
“Possibly”, “Probably”, or “Definitely”.   Always inc lude the following here:   
i. STRC clinician name and  comments   
ii.Date of last dose before the event   
iii. Is suspension of the protocol needed?  Y/N  
7. Treating Physician  comments   
8. PI comments, if  available   
9. Protocol Attribution after discussion with STRC  clinician   
10. Outcome (Fatal/Died, Intervention for AE Continues, Migrated AE, 
Not Recovered/Not Resolved, Recovered/Resolved with Sequelae, Recovered/Resolved 
without  Sequelae,  Recovering and  Resolving)   
11. Consent form Change  Required?  Y/N  
12. SAE Classification *This is re quired  in order for the email notification to be  sent*  
13. Adverse Event Details – Enter all details for each AE associated with the  SAE.   
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 71 of 85 a. Course start  date   
b. Category   
c. AE Detail  
d. Comments   
e. Grade/Severity   
f. Unexpected  Y/N  
g. DLT Y/N  
h. Attributions   
i. Action   
j. Therapy   
k. Click ADD to attach the AE Detail to the  SAE.   
14. Enter Date Notified STRC --  *This is required for the email notification to be  sent*   
15. Click  Submit.  The auto -generated notification email will disseminate within 5 minutes. If 
you do not receive an em ail within 5 minutes, check that you have entered the “Date Notified 
STRC”  and the “SAE Classification”.  If these have been entered and the email still has not been 
received, take a screen shot of the SAE in  WISER  and immediately email  it out to  all of the STRC 
members listed in this SOP.  In the subject line, indicate that this is a manual transmission of the SAE 
in lieu of the auto -generated email.  It is required that a notification goes to the STRC members 
immediately  so that their assessment can be obtai ned within the  24 hour  time frame 
requirement.  Contact the Cancer Center Programmer/Analyst to alert that there is an issue with 
the auto -generated email.   
  
The Clinical Members of STRC to Notify by Phone or  Page:  
Bayard Powell, MD  – Director- at-Large, W FBCCC; Section Head,  Hematology/Oncology  6- 
Glenn Lesser, MD  – Hematology Oncology 6 - 
Stefan Grant, MD, JD -Hematology Oncology 3 - 
Jimmy Ruiz, MD -Hematology Oncology 6 - 
Mercedes  Porosnicu, MD - Hematology Oncology 6 - 
         Michael Farris, MD  – Radiation  Oncology 3 - 
  
Definition of  Unavailable:  
As a gener al guideline if the first clinician that is contacted does not respond to the phone  call or page 
within 30 minutes, then initiate contact with a different STRC clinician. Allow up to  30 minutes for the 
new STRC clinician to respond to a phone call or page before  contacting  another member. These 
times (30 minutes) are a general guideline. Best judgment as a  clinical research professional should 
be used giving considerations of the time of day, severity of  the SAE, and other circumstances as to 
when it is app ropriate to contact backup clinicians. If  the event occurs near the end of day, then leave 
messages (voice or email) as appropriate  and proceed with submitting the STRC notification form. It is 
important to take reasonable  steps and to document that some t ype of contact has been initiated to 
one or more of the  clinical members of  STRC.   
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 72 of 85   
STRC CLINICAN  RESPONSIBILITY:   
It is the responsibility of the STRC clinician to review all reported events, evaluate the events  as they 
are reported; and communicate a response to the Investigator, event reporter and  the members of 
STRC. The review will include but not be limited to the information reported;  there may be times 
when additional information is needed  in order for  an assessment to be  made  and further 
communi cation directly with the investigator may be warranted. STRC reserves  the right to disagree 
with the Investigator's assessment. If STRC does not agree with  the 
Investigator,  STRC  reserves  the right  to suspend  the trial pending further  investigation.  If there is any 
immediate danger or harm that could be present for a future patient based on 
the information  provided  in the STRC  report  then  an immediate  suspension  of enrollment 
should  be considered.   
  
AMENDMENTS TO PREVIOUS  REPORTS   
If all pertinent informat ion is unavailable with the initial submission, once the additional information 
is available  do not submit a new report . Rather, go to the original email that  was sent to the STRC 
and using that email “reply to all”. Entitle this new email “ Amendment  for ( list date of event and 
patient ID)” this will avoid duplications of the same event. List the  additional information being 
reported. This information needs to be  entered into  WISER as  well. To do this, go to the Subject 
console and click SAEs on the left co lumn. Click on  the 
appropriate  SAE number  that needs  updating.  Then  click  update.  This will allow  additional  informatio
n to be  added   
    
Acronyms   
AE – Adverse  Event   
STRC -Safety and Toxicity Review  Committee  
SAE-Serious Adverse  Event   
WFBCCC  – Wake Forest Baptist Comprehensive Cancer  Center   
NCI-National Cancer  Institute  
WISER –Wake Integrated Solution for Enterprise Research   
Screen  Shots:   
  
The following screen shots come from the SAE Console within the Subject Console in  WISER.   
  
Screen Shot 1:  
Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 73 of 85   
Screen Shot  2:
  
  
Screen Shot  3:  

Single -arm phase II combination study of low -dose paclitaxel with pembrolizumab in platinum -
refractory urothelial carcinoma  
Comprehensive Cancer Center of Wake Forest University (CCCWFU)  
CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 74 of 85   
  
 Screen Shot 4
 

   ORIS ID: _______________________   CCCWFU #  
   
Protocol version date 03/10/2020       Page 75 of 85 Appendix E – TUMOR RESPONSE WORKSHEET (RECIST v1.1)  
 Target Lesions  TARGET  Lesions  Lesion  Site Nodal/Non -
nodal  
(measure shortest 
diameter for 
nodal)  Imaging  
(ie,CT, MRI)  Baseline  
Date : Cycle_____ 
Date : 
 Cycle_____ Date : 
 Cycle_____ Date : 
 Cycle_____ Date : 
 Cycle_____ Date : 
 
01    mm mm mm mm mm mm 
02    mm mm mm mm mm mm 
03    mm mm mm mm mm mm 
04    mm mm mm mm mm mm 
05    mm mm mm mm mm mm 
Sum of Diameters  mm mm mm mm mm mm 
% Change (% ∆)  from Baseline or Nadir* & absolute value (AbV)  
 NA 
        
          NA % ∆ 
                        
        AbV     
Target Lesion Response        N/A       
 Non -Target Lesions  NON -TARGET  Lesions  Lesion  Site Nodal/Non -
nodal  Imaging  Baseline  Cycle_____ Cycle_____ Cycle_____ Cycle_____ Cycle_____ 
01          
02          
03          
04          
05          
06          
07          
08          
09          
10          
Non -Target Lesion Response  N/A       
 New Lesions  New 1    N/A      
2    N/A      
3    N/A      
Overall Tumor Response  
 
 
  
Cycle___   
Cycle___   
Cycle___  
  
Cycle___  
  
Cycle___  
     
     
Radiologist Signature :       
Treating Physician Signature :       
PI Signature:        
*Terms & Calculations         
Baseline:  The set of data collected prior to randomization 
 Nadir: The lowest point    

ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 76 of 85 WEEK / CYCLE # INVESTIGATOR PRINTED NAME INVESTIGATOR SIGNATURE  DATE 
    
    
    
    
    
    
    
    
    
 
 
 
TARGET AND NON-TARGET LESIONS  
TARGET LESION  NON-TARGET LESION  NEW LESION  OVERALL RESPONSE  
CR CR NO CR 
CR NON-CR/N ON-PD NO PR 
CR NOT EVALUATED  NO PR 
PR NON-PD OR NOT ALL 
EVALUATED  NO PR 
SD NON-PD OR NOT ALL 
EVALUATED  NO SD 
NOT ALL 
EVALUATED  NON-PD NO NE 
PD ANY YES OR NO PD 
ANY PD YES OR NO PD 
ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 77 of 85 ANY ANY YES PD 
 
Non-Target Disease Only  
Non-Target Lesions  New Lesions Overall Response  
CR No CR 
Non-CR/Non -PD No Non-Cr/Non -PD 
Not All Evaluated  No NE 
Unequivocal PD  Yes or No  PD 
Any Any PD 
 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 
and NE = not evluated  
 
Target Lesion Timepoint Assessment  
 
Target Lesion Response  Definition  
Complete Response (CR)  Disappearance of all target lesions. Pathological lymph nodes 
(whether target or non- target) must have reduction in short axis 
to < 10 mm  
Partial Response (PR)  At least a 30% decrease in sum of diameters, taking as reference 
the baseline sum diameters  
Progressive Disease (PD)  At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum  on study based on all target 
lesions recorded since the treatment started. The sum must also demonstrate an absolute increase o f at least 5 mm. (Note: the 
appearance of one or more new lesions is also considered 
progression)  
Stable Disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum 
diameters whil e on study  
Not Evaluated (NE)   Any target lesion present at baseline which was not assessed or 
was unable to be evaluated leading to an inability to determine the status of that particular tumor for that time point  
Not Applicable (NA)  No target lesions were identified at baseline  
 
Non-Target Lesions Timepoint Assessment  
 
Non-Target Lesion Response  Definition   
Complete Response (CR)  Disappearance of all non -target lesions. All lymph nodes must be 
non- pathological in size (< 10 mm short axis)  
Non-Complete Response/Non - Persistence of one or more non- target lesions not qualifying for 
ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 78 of 85 Progressive Disease  either CR or PD  
Progressive Disease (PD)  Unequivocal progression of existing non- target lesions.  
•  subjects with measurable non -target disease –  
Substantial worsening such that the overall tumor 
burden has increased sufficiently to merit 
discontinuation of therapy.  
•  subjects with non -measurable disease – Increase in 
overall tumor burden comparable in magnitude to the 
increase required to declare PD for measurable disease.  
Not Evaluable (NE)  Any non- target lesion present at baseline which was not 
assessed or was unable to be evaluated leading to an inability to determine status 
Not Applicable (NA)  No non- target lesions identified at baseline  
 
CCCWFU #88215  
v. 6-8-2016 
Page 79 of 85 
Protocol version date 03/10/2020  Appendix F –  Baseline Data Collection Form  
 
Date of visit _ _/_ _/_ _  
 
1. Oncologic history  
 
a. Most immediate prior cancer therapy (select one):  
 chemotherapy    radiation    surgery    hormone   other: ___________________________ 
 
b. Specify most immediate prior cancer therapy: ______________________________________________ 
 
Dates of administration:  Started: __ __ / __ __ / __ __  Stopped:  __ __ / __ __ / __ __  
 
Dose ___________ & total # of treatments ________ 
 
c. Other prior cancer therapies (excluding 1b.) for most recent cancer. Mark all that apply:  
     None   Chemotherapy   Radiation   Surgery   Hormone therapy   Other: _____________  
 
Regimen Name  Total # of Treatments  Date of Last Treatment  
1.   
2.   
3.   
4.   
5.   
6.   
7.   
8.   
9.   
10.   
 
Site of RT  Total Dose in Gy  Date of Last Treatment  
1.   
2.   
3.   
4.   
5.   
 
Type of surgery  Date of surgery  
1.  
2.  
 
Hormone Therapy Name  Dose  Date of Last Treatment  
1.   
2.   
 
Other  Dose  Date  of Last Treatment  
1.   
2.   
 
2. Date of baseline imaging:  __ __ / __ __ / __ __  
 
Sites of disease: ___________________________________________________________ 
 
Imaging modality:   CT scan     PET scan   MRI scan    Bone scan   Other, specify _________  
  
CCCWFU #88215  
v. 6-8-2016 
Page 80 of 85 
Protocol version date 03/10/2020  3.   Medical history (check all that apply):  
 Myocardial infarction  
 Congestive heart failure 
 Peripheral vascular disease 
(claudication, arterial bypass, untreated 
aneurysm (≥6cm)  
 Cerebrovascular disease (history of TIA 
or CVA)  
 Dementia  
 Chronic pulmonary disease (with 
symptomatic dyspnea)  
 Connective tissue disease (SLE, 
polymyositis, mixed CTD, polymyalgia 
rueumatic, moterate to severe RA)   Peptic ulcer disease  (bleeding ulcer)  
 Liver disease (on treatment, cirrhosis without 
portal hypertension, chronic hepatitis); check 
here if mild      
 Diabetes  
end organ damage? Yes  No  
 Hemiplegia  
 Leukemia  
 Lymphoma  
 AIDS 
 Other major medical condition; specify  
___________________________________
 
4.   Concurrent medications and supplements  
a. List all prescription and over -the-counter medications  (includes prescription supplements)      
Medication Name  Is it PRN?  Medication Name  Is it PRN?  
1. yes          no  11. yes          no  
2. yes          no  12. yes          no  
3. yes          no  13. yes          no  
4. yes          no  14. yes          no 
5. yes          no  15. yes          no  
6. yes          no  16. yes          no  
7. yes          no  17. yes          no  
8. yes          no  18. yes          no  
9. yes          no  19. yes          no  
10. yes          no  20. yes          no  
 
b. List all supplements (excludes prescription supplements)  
Supplement Name  Is it PRN?  Supplement Name  Is it PRN?  
1. yes          no  11. yes          no  
2. yes          no  12. yes          no  
3. yes          no  13. yes          no  
4. yes          no  14. yes          no 
5. yes          no  15. yes          no  
6. yes          no  16. yes          no  
7. yes          no  17. yes          no  
8. yes          no  18. yes          no  
9. yes          no  19. yes          no  
10. yes          no  20. yes          no  
 
5.   Physical exam:  
Derm –  WNL   Abnormal, specify ______________________________  
HEENT –  WNL   Abnormal, specify ______________________________  
CV –  WNL   Abnormal, specify ______________________________  
Pulm –  WNL   Abnormal, specify ______________________________  
GI –  WNL   Abnormal, specify ______________________________  
Other –  Abnormal, s pecify ____________________________  
 
6.   Vital signs:  
a. HR_________ 
b. BP____ /____ c. RR_________ 
d. Temp  _______ (°F) 
CCCWFU #88215  
v. 6-8-2016 
Page 81 of 85 
Protocol version date 03/10/2020  e. Weight ______(kg)  f. Height  ______(cm)  
7.   ECOG Performance Status (check one):  
 
GRADE  Description  
   0 Fully active, able to carry on all pre -disease performance without restriction  
   1 Restricted in physically stren uous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work  
   2 Ambulatory and capable of all self care, but unabl e to carry out any work activities. Up and 
about more than 50% of waking hours  
   3 Capable of only limited self care, confined to bed or chair more than 50% of waking hours  
   4 Completely disabled. Cannot carry on any self care. Totally confined to bed or chair  
   5 Dead  
 
8.   Documentation of negative pregnancy test for women of child- bearing potential? 
Yes    No , reason ____________________    Not applicable  
 
9.   Blood Draws:  
 
a.   CBC with Differential , Date  drawn __ __ /__ __ / __ __  
 
b.   Serum Chemistry, Date drawn  __ __ /__ __ / __ __  
 
c.   Urinalysis Date __ __ /__ __ / __ __  
 10.   Metastatic tumor biopsy:  
 a.   Date __ __ /__ __ / __ __  
 b.   Site of biopsy:______________________________ 
11.   Archival tumor tissue:  
 a.   Date __ __ /__ __ / __ __  
 b.   Site from which tissue obtained:______________________________ 
 
     
 
 
     
 
 
  
 
CCCWFU #88215  
v. 6-8-2016 
Protocol version date 03/10/2020    Page 82 of 85 
 Appendix G –  Follow -up Data Collection Forms  
 
Follow -Up Visit:   Cycle 1     Cycle 2     Cycle 3     Cycle 4     Cycle 5     Cycle 6   Cycle 7  Cycle 8    
End of Treatment       Follow -up 
 
Date of Visit: __ __ / __ __ / __ __  
 
1. Medical History               Medical Conditions, new from baseline (specify)___________________________  
 Hospitalizations since last visit (specify)_________________________________  
 
 
2.   Concurrent medications  and supplements        
a. List all prescription and over -the-counter medications  (includes prescription supplements) .    
Medication Name  Is it PRN?  Medication Name  Is it PRN?  
1. yes          no  11. yes          no  
2. yes          no  12. yes          no  
3. yes          no  13. yes          no  
4. yes          no  14. yes          no  
5. yes          no 15. yes          no  
6. yes          no  16. yes          no  
7. yes          no  17. yes          no  
8. yes          no  18. yes          no  
9. yes          no  19. yes          no  
10. yes          no  20. yes          no  
 
b. List all supplements (excludes prescription supplements).  
Supplement Name  Is it PRN?  Supplement Name  Is it PRN?  
1. yes          no  11. yes          no  
2. yes          no  12. yes          no  
3. yes          no  13. yes          no  
4. yes          no  14. yes          no  
5. yes          no  15. yes          no  
6. yes          no  16. yes          no  
7. yes          no  17. yes          no  
8. yes          no  18. yes          no  
9. yes          no  19. yes          no  
10. yes          no  20. yes          no  
 
3.   Physical exam:  
Derm –  WNL   Abnormal, specify ______________________________  
HEENT –  WNL   Abnormal, specify ______________________________  
CV –  WNL   Abnormal, specify ______________________________  
Pulm –  WNL   Abnormal, specify ______________________________  
GI –  WNL   Abnormal, specify ______________________________  
Other –  Abnormal, s pecify ____________________________  
4.   Vital signs:  
g. HR_________ 
h. BP____ /____ 
i. RR _________ 
j. Temp  _______ (°F) 
k. Weight ______(kg)  l. Height  ______(cm)  
ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020   Page 83 of 85 
  
 
5.  ECOG Performance Status (check one):  
GRADE  Description  
   0 Fully active, able to carry on all pre -disease performance without restriction  
   1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work  
   2 Ambulatory and capable of all self care, but  unable to carry out any work 
activities. Up and about more than 50% of waking hours  
   3 Capable of only limited self care, confined to bed or chair more than 50% of 
waking hour s 
   4 Completely disabled. Cannot carry on any self care. Totally confined to bed or 
chair  
   5 Dead  
 
6.  Documentation of negative pregnancy test for women of child- bearing potential? 
Yes    No , reason ____________________    Not applicable 
 
 
7.  Blood Draws  
 
a.   CBC with Differential , Date  drawn __ __ /__ __ / __ __  
 
b.   Serum Chemistry, Date drawn  __ __ /__ __ / __ __  
 
 c.   Urinalysis Date __ __ /__ __ / __ __  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020   Page 84 of 85 
 Appendix H – Treatment Response Evaluation  
 
Overall Response Rate is the primary objective for this study.   Patients will be evaluated with 
imaging  at baseline, every 9 weeks (+/ -7days), and end of treatment. At the end of treatment, if 
no progression, patients will be evaluated with imaging every 3 months (+/ -10 days) for 1 year.   
Study Visit:   
 Week 9  ( ± 7 days)  
 Week 18  ( ± 7 days)  
 Week 27  ( ± 7 days)  
 Week 36  ( ± 14 days)  
 End of Treatment  
 3 months ( ± 10 days)  post Treatment  
 6 months ( ± 10 days)  post Treatment  
 9 months ( ± 10 days)  post Treatment   
 12 months ( ± 10 days)  post Treatment   
 Other visit: (please specify) ________________  
 
Date of Scan: ___ ___ /___ ___ /___ ___  
 
Imaging Modality:   CT  PET/CT  MRI   Other____________  
 
Evaluation of imaging per clinical review – measurable disease  
 
   Complete Response (CR)  
 
   Partial Response (PR)  
 
   Progressive Disease (PD) : Date of progression ___ ___ /___ ___ /___ ___ 
 
   Stable Disease (SD)  
 
   N/A  
 
Evaluation of non- measurable disease (e.g., pleural effusion)  
 
   Complete Response (CR)  
 
   Non-CR/Non -PD 
 
   Progressive Disease (PD) : Date of progression ___ ___ /___ ___ /___ ___ 
 
   N/A  
  
 
Treating Physician Signature: ______________________ Date: ___ ___ /___ ___ /___ ___  
 PI Signature: ___________________________________ Date: ___ ___ /___ ___ /___ ___  
ORIS ID_____________  Date: __ __/__ __/__ __  CCCWFU # 88215  
 
Protocol version date 03/10/2020       Page 85 of 85 
 Appendix I – Adverse Event Log  
  
WFBCCC Adverse Event (AE) Log    
PI: _________________  Subject PID: _________________  MRN: ________________  
Cycle #:  Cycle Start Date:  Cycle Start Time:  Cycle End Date :  Cycle End Time:  
Adverse Event CTC 
Term  Lab 
Value  
 Grade   
(1-5) per 
CTC Start 
Date  Attribution   
DEF= Definite  
PROB = Probable  
POSS = Possible  
UNLK = Unlikely  
UNRL = Unrelated  Treating MD 
Initials  + 
Date  End Date  Expected   
N= No  
Y= Yes  *Serious Adverse 
Event Detail:     
NO= No  
LT= Life Threatening  
DTH= Death  
DIS= Disability  
HOS = Hospitalization  
CA= Caused 
congenital anomaly  
RI= Required 
intervention to prevent 
impairment  Dose 
Limiting 
Toxicity 
(DLT)  
N= No  
Y= Yes  Action Taken 
NO= None  
DR= Dose 
Reduced  
RI= Regimen 
Interrupted  
TD= Therapy 
discontinued  
INTR = Interrupted 
then reduced  Therapy 
Given  
NO= None  
SYM = 
Symptomatic  
SUP= 
Supportive  
VSUP = 
Vigorous 
Supportive  Reportable?    
IRB= IRB 
STRC= STRC 
FDA= FDA 
SPON= Sponsor  
(Mark all that 
apply)  Adverse 
Event 
Report 
(AER) 
filed?  
N= No  
Y= Yes  Outcome  
R= Recovered  
TX= Still under 
treatment or 
observation  
A= Alive with 
Sequalae  
D= Died  
                         
                         
                         
                         
                         
               
               
               
               
               
               
               
 
*Serious Adverse Event: Hospitalization; Disability; Birth Defect; Life -threatening; Death.   
 
CTCAE Version 4 - http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_8.5x11.pdf   
 
STRC = Safety and Toxicity Review Committee  Version 
10/30/17  